





The effect of 1’ acetoxychavicol acetate on cell 
proliferation, metastasis, and angiogenesis in human 
endocrine-resistant breast cancer cells 
 
 
Thesis submitted in accordance with the requirements of 
Chulalongkorn University and the University of Liverpool for the 












Background: Oestrogen receptor (ER)-positive breast cancer patients have a good prognosis, 
but 30% of these developed resistance through hyperactivation of PI3K/AKT, ERK1/2, and 
NFκB, which interconnected with ER signalling. In this study, the effects of 1’ acetoxychavicol 
acetate (ACA), a plant-metabolite acetate ester compound with an NF-kB inhibitory activity, 
were investigated in a panel of endocrine-resistant breast cancer cells.  
Methods: Plant material was purified by chromatographic methods and followed by structural 
identification using nuclear magnetic resonance and mass spectroscopy. In vitro and in vivo 
antiproliferative effects of ACA were studied in MCF7/LCC2 and MCF7/LCC9 endocrine-
resistant cells using the MTT assay and the zebrafish xenograft model respectively. Anti-
invasion of ACA was performed by the matrigel invasion assay, while its mechanism of action 
was elucidated through molecular docking simulation, real-time PCR, and western blotting. 
Western blot analysis was also used to investigate its effect on apoptosis.   
Results: ACA inhibited the proliferation of MCF7, MCF7/LCC2, and MCF7/LCC9 cells at a 
concentration- and time-dependent fashion. This was associated with down-regulation of 
HER2 receptor, estrogen receptor coactivator (NCOA3), pERK1/2, pAKT, and proliferative 
markers (CCND1, C-myc). While in vivo, significant reduction in the tumour mass of ACA-
treated zebrafish engrafted MCF7/LCC9 groups was observed compared to the control 
treatment. Furthermore, the anti-invasive effects of ACA were confirmed in vitro by the 
matrigel invasion assay and with reduction in the expression levels of CXCR4, uPA and 
proangiogenic factors, VEGF and FGF2 in ACA-treated cells compared to untreated control. 
The repressed expression of uPA and FGF2 was also validated by molecular docking analysis. 
Moreover, ACA-treated cells exhibited lower expression levels of the anti-apoptotic BCL2 and 
MCL1 proteins in addition to increase JNK/SAPK expression and enhance PARP cleavage, 
indicating apoptotic cell induction by ACA.  
 ii 
Conclusion: This research suggested that the ACA inhibited cell proliferation and induce 
apoptosis in breast cancer cells through HER2/MAPK/ERK1/2 and PI3K/AKT pathways. In 
addition, the anti-angiogenic and anti-invasive activity of ACA was through the 
downregulation of VEGF, FGF2, uPA, and CXCR4.  
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1.1 Background  
According to the National Cancer Registry (NCR) in 2017, 1.762 million new cancer 
cases and approximately 606,880 deaths were predicted in the United States (1). The disease 
causes a substantial issue for patients and healthcare systems with up to 10% of cancer costs in 
total (2).  In 2019, prostate, pulmonary, and colorectal cancers (CRCs) estimate for 42% of 
cases in male, prostate cancer alone estimating around 1 in 5 new diagnosed-cases (1). In the 
female, the three most common cancers are breast, lung, and colorectum, which represent 50% 
of all new diagnosed-cases; breast cancer alone considers for 30% of total new cancer 
diagnoses in women (1). In 2020, 1,806,590 new cancer cases and  around 606,520 cancer 
deaths are projected to occur in the US (3). Nevertheless, the therapeutic practice that had been 
implemented in the therapy of breast cancer in the Western for the past 30 year-time and in 
Europe have increased, the age-standardised, 5-year relative survival rates was from 73% to 
83% during 1992 and 2008 (4). One major issue regarding the medical treatment of breast 
cancer in Europe is the enormous cost in contemporary financial circumstances of healthcare 
system (5). The system to predict and diagnose using biomarkers could ameliorate the therapy 
and the cost, however, the process to efficiently develop precise and promised biomarkers were 
quite difficult (5). Further challenges for cancer therapy were the new cancer drug targets to 
fight against cancer-resistant types as well as the bench to bedside efforts to implement the 
knowledge acquired from translational research to the patients (5). 
Around 70% of breast cancer patients express oestrogen receptor alpha (ERα) and are 
classified as ER-positive (+) therefore, ER signalling plays a crucial role in the pathogenesis 
of breast cancer (6). Consequently, therapeutic management aims to reduce the ER-ligand 
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oestrogen or to inhibit ER signalling (6). Tamoxifen is the first-line adjuvant therapy for early 
and advanced ER positive breast cancer in pre- and post-menopausal women (7). Tamoxifen 
is the first-line choice for hormonal therapy in both early and advanced breast cancer patients 
for more than 30 years (8). The tamoxifen-adjuvant treatment has significantly improved 
disease-free survival and diminished mortality rate of breast cancer patients (9). In some cases, 
the use of tamoxifen is for neoadjuvant therapy for women with a high risk of breast cancer 
occurrence, aiming for prophylaxis the disease, but the concern of risks from adverse drug 
reaction outweighs the advantages is still required more information to be confirmed (10, 11). 
Also, around one-half of advanced-stages breast cancer patients do not adequately respond to 
tamoxifen treatment since the first time (de novo resistance) (12, 13). Additionally, some 
patients respond sufficiently to tamoxifen at first, and after the use of tamoxifen for 5-10 years 
the  disease may relapse and cancer cell develop resistance to tamoxifen  (acquired resistance) 
(12, 13). The de novo and acquired resistance of cancer to tamoxifen treatment can be caused 
from various molecular mechanisms and molecules, including single nucleotide 
polymorphisms (SNPs) of cytochrome P450 2D6 (CYP2D6), the loss of ER expression and 
function, altered expression patterns of co-regulatory proteins, overexpression of human 
epidermal growth factor receptor 2 (HER2/neu), hyperactivation of a phosphatidylinositol 3-
kinase (PI3K) signalling pathway as well as the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) activation (14-16). Fulvestrant, a later anti-oestrogenic drug in the 
selective oestrogen receptor downregulators class, has been recently revealed the clinical 
efficiency in patients relapsed disease after the treatment of tamoxifen and aromatase inhibitors 
(AIs) (17). In this regard, more translational studies have been carried out for supporting the 




1.2 Breast cancer 
Breast cancer is the second leading cause of global women-cancer mortality (19). 
Statistically, 10 per cent of female in the UK and the US experienced the disease in their 
lifetime (19). The incidence of breast cancer was higher in the western, and many risk factors 
involved in the pathogenesis such as non-adjustable and modified risk factors  (20). Non-
adjustable risk factors related to breast cancer are gender, age, and family history (20). The 
non- adjustable risk factors are difficult to control (20). On the other hand, the modified risk 
factors such as dietary lipid and alcoholic intake, obesity especially in postmenopausal age, 
hormonal exposure are the most interest regarding breast cancer prophylactic strategy (21). 
More interestingly, endogenous and exogenous endocrine factors,  mammographic density and 
previous benign disease are also the non-favourable causes of the disease (22). The mutation 
of genetic factors such as the breast cancer gene (BRCA) 1 and 2, tumour protein (P53),  
phosphatase and tensin homologue deleted on chromosome ten (PTEN), and overexpression 
of HER-2 antigen are considerable issue for breast cancer patients (19).  In addition, the 
proliferative marker Ki-67 is also significant to determine for the prognosis of disease 
progression (23). Therefore, breast cancer cannot be seen as a single disease. Breast cancer can 
be classified into 4 major types by histopathological staining based on the expression of 
oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) or the lack of these (24). However, breast cancer heterogeneity and the 
identification of additional molecular markers makes this classification a more complicated 






1.2.1 Molecular Subtypes of Breast Cancer 
The last decades, several studies highlighted the heterogenicity of breast cancer and led 
to the identification of distinct molecular subtypes (5, 25, 26). The detection of breast tissue 
molecular subtypes is crucial in terms of the first-line treatment regimen. There are three 
primary receptors to be determined for the identification of breast cancer subtypes which are 
ER, PR and HER2 receptors.  Breast cancer molecular subtypes can be distinguished into four 
main subtypes which are;  
1. Luminal A breast cancer is hormone-receptor-positive (ER and/or PR positive), and 
HER2 negative. This type of breast cancer could represent a low level of  Ki-67 protein, which 
describe the low aggressiveness that bears a good prognosis compared to other types (27). 
2. Luminal B breast cancer is also hormone-receptor-positive (ER and/or PR positive), 
and either HER2 positive or HER2 negative and it is more common for the luminal B subtype 
to express high Ki-67 protein level. This type of breast cancer shows a more aggressive and 
poorer prognosis compared to the luminal A subtype (27). 
3. HER2-enriched breast cancer is hormone-receptor-negative (ER and PR negative), 
and HER2 positive. HER2-enriched tumours were found approximately 20-30% of all breast 
tumours and were more aggressive than the luminal subtypes (28). With regards to the 
overexpression of the HER2 receptor, the HER2-targeted therapy;  trastuzumab, and T-DM1 
or ado-trastuzumab emtansine and pertuzumab, and tyrosine kinase inhibitors; lapatinib have 
been approved to give effectiveness for the patients (27). 
4. Triple-negative (TN) or basal-like breast cancer is hormone-receptor-negative (ER 
and PR negative), and HER2 negative and commonly be detected the mutation of breast cancer 
gene 1 (BRCA1). The phenotype of the TN is mainly basal-like tumour as it shows various 
degree of basal-like biomarkers (29, 30). Clinically, this type of breast cancer was the poorest 
prognosis compared to other subtypes (31). 
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Table 1.2.1.1 Molecular subtypes of breast cancer (32-34) 
Subtypes ER PR HER2 
Luminal A + +/- - 
Luminal B + +/- + 
HER2-enriched  - - + 
Triple negative - - - 
 
 
1.2.2 The ER structures and signalling pathways  
Oestrogens are steroid hormones that regulate growth, differentiation, and function in 
a broad range of many tissues such as breast, uterus, cardiovascular system, brain and 
urogenital tract of both males and females (35). 
Oestrogens are the group of sex hormone that has a broad range of function regarding 
the regulation of female characteristics and the proliferation and differentiation of tissues, 
including breast, cardiovascular system, brain and urogenital tract of both male and female 
(35). Apart from that oestrogens are very crucial in the development process of mammary gland 
as of their potent mitogenic activity, the level of oestrogens; oestradiol (E2) in particular and 
its signalling through ERs are involved in the tumourigenesis of breast tissue (35). In order to 
exhibit the oestrogenic response, E2 will bind to the ER, which is a steroid receptor located in 
the cytoplasm to drive the ligand-induced transcription of ER-regulated genes (35). There were 
two main superfamilies of ERs that have been specified, ERα (in 1986) and ERβ (in 1996) 
(36). ERα and ERβ were transcribed by distinct genes on chromosome 6 and 14, ERβ was 
identified to co-expression with ERα; however, its roles on breast tumours and malignancy was 
still controversial (37, 38).  
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ERα and ERβ have a high level of homology in their DNA-binding domain (DBD; 97% 
amino acid identity) and ligand-binding domain (LBD; 59% amino acid identity) (37). The 
structure of ERα and ERβ composed of six domain-shared structure; domain A - F (Figure 
1.2.2.1), Domain A/B (non-ligand binding domain) at the N-terminus was the location of the 
activation function 1 (AF1), responsible for the transcriptional activity of the ER without E2 
binding (37). Domain C was the DBD comprised of two zinc-finger structure which was crucial 
for ligand-ER complex dimerisation and the binding of the ligand-ER complex to the specific 
consensus sequence of the DNA in the nucleus (37). Domain D was the joint between domain 
C and E that was important for the nuclear localisation of the E2-ER complex into the nucleus 
(37). Domain E (LBD) was the part for E2 to bind with ER and composed of a second nuclear 
localisation signal, a dimerisation locality and a twelve-helix region required for ligand binding 
(37). The E domain was also the location of activation function 2 (AF2) was another section 
that involved in ligand-dependent activation of ER. At the end of the C-terminus, there was a 
domain F which was the region-mediated AF1 and AF2 (37). 
 
Figure 1.2.2.1. Schematic representation of the functional domains of human ERα and ERβ 
(37). This figure shows the structural domains of ERα and ERβ which consist 5 subunits 
namely, A/B, C, D, E, and F that function differently.  
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There are two distinct mechanisms of ligand-dependent activation of ERα signalling 
related to cell survival and proliferation, which are the classical genomic and non-classical 
genomic signalling pathway (37). The classical genomic pathway is initiated since E2 bind to 
the binding site of ERα in the cytoplasm, the binding induces the conformational changes of 
the receptor and driven the removal of chaperone proteins (heat shock protein 90; Hsp90) 
allowing the dimerisation of the receptor and the trans-localisation into the nucleus. This 
ligand-ERα complex will then bind to the consensus sequence of the DNA called oestrogen-
responsive element (ERE) (37). The binding of the ligand-ERα complex can bind directly to 
the ERE (classical-genomic pathway) or indirectly through the protein-protein interaction with 
the activation protein 1 (AP1) or special protein 1 (SP1) sites  (nonclassical-genomic pathway) 
at the promoter region  (steroid-responsive element; SRE) of targeted genes, resulting in the 
recruitment of ER co-regulatory proteins; coactivators or corepressors and drives or represses 
the transcriptional activity of ER-regulated genes (Figure 1.2.2.2a - b) (37).  
There are also the non-genomic pathways of ER signalling via activation of 
Ras/Raf/ERK1/2 and PI3K/AKT pathways through the binding of growth factors with the 
receptor of tyrosine kinases (RTKs) and mediate the genes, including cyclins, cyclin-dependent 
kinases and cyclin-dependent kinase inhibitors (39). These signalling the E2-ER complex is not 
translocation into the nucleus itself, instead ERK1/2 or AKT act as the transcription factor (39). 
Apart from that, E2 can bind to membranal ERα and activate the PI3K pathway, which will 
then activate the AKT to act as the transcription factor and translocation to the nucleus then 
bind with a responsive element (RE) of the DNA  to drive the transcription of the genes (Figure 






Figure 1.2.2.2. The ER signalling pathways. The three distinguish pathways of ER; classical 
genomic (a), non-classical genomic (b)  and the non-genomic (c and d) pathways of ER (39). 
  
1.2.3 Hormonal treatment of breast cancer 
The treatment of breast cancer was based on several key considerations, including 
molecular subtypes, disease stage, tumour histology, and menopausal status (40). In the early 
stage of breast cancer patients are recommended for mastectomy and radiotherapy, however, 
systemic therapy is also recommended for almost all patients, and it is also prime for advanced-
stage breast cancer patients (5, 40).  
There are three drug classes of hormonal therapy for hormone receptor-positive breast 
cancer. Firstly, selective oestrogen receptor modulators (SERMs), the prototype of this group 
is tamoxifen (19). Secondly, selective oestrogen receptor down-regulators (SERDs), 
fulvestrant is the prototype of the group. Finally, aromatase inhibitors (AIs), anastrozole is the 





1.2.3.1 Selective Estrogen Receptor Modulators (SERMs) 
The major drugs in this group are tamoxifen (TAM, the prototype) and raloxifene. 
These two drugs have both the oestrogenic agonist and antagonist depending on the tissue 
subtypes (21).  TAM and raloxifene work by binding to the ER and trigger or inhibit the 
signalling pathways of the ER (21). Tamoxifen citrate is the first drug launched in this group, 
which is the prodrug required the phase I metabolism of the liver to be an active metabolite 
(21). Raloxifene, the second drug of this group, also functions as both oestrogenic agonist and 
antagonist, but the main different activity from TAM is that raloxifene does not possess the 
agonistic effect at endometrium (21).  TAM was recommended to use as first-line adjuvant 
therapy after the mastectomy or radiation in both male and female with metastatic breast cancer 
and decrease the risk of ductal carcinoma in situ (DCIS) in women as well as diminish the 
disease occurrence of women with a high risk of breast cancer (21). However, there was a 
concern raised TAM usage, which was the risen risk of uterine or endometrial cancer.  (41). 
 
Table 1.2.3.1.1. Adverse drug reactions of tamoxifen (42) 
Organ systems Adverse drug reactions of tamoxifen 
Cardiovascular Vasodilatation, flushing, hypertension, peripheral edema  
Endocrine & metabolic Hot flash, fluid retention, menstrual disease, weight loss, 
amenorrhea 
Neuromuscular & skeletal Weakness, arthritis, arthralgia 




1.2.3.2 Selective Estrogen Receptor Down-Regulators (SERDs) 
This class is a pure anti-oestrogenic activity through the enhance of internalisation and 
degradation of the ER and PR; thus, this class is more potent than SERMs (19). Fulvestrant 
(ICI182,780) is the first drug and the prototype of this group, which works via the binding of 
ER and produce no intrinsic activity (antagonistic effect) with a 100-times higher affinity 
compared to TAM (19). Unlike TAM, fulvestrant has no stimulatory effect on the uterus; 
therefore, it reduces the adverse events of uterine or endometrial cancer (19).  Fulvestrant was 
approved for postmenopausal women with hormone receptor (HR)-positive metastatic breast 
cancer when disease progression after the endocrine therapy (19). It was also approved for the 
combined treatment with palbociclib (a cyclin-dependent kinase 4/6 inhibitors) for breast 
cancer patients with HR positive, HER2 negative and advanced or metastatic breast cancer 
(MBC) whose the disease has progressed after the endocrine therapy (43-45). 
 
Table 1.2.3.2.1. Adverse drug reactions of fulvestrant (43) 
Organ systems Adverse drug reactions of fulvestrant 
Central nervous system  Fatigue, headache, hot flash  
Hematologic & oncologic Anemia, bleeding disorders 








1.2.3.3 Aromatase Inhibitors (AIs) 
The drug class is preferable for postmenopausal breast cancer patients more than other 
endocrine therapy (46). There are two types of AIs which are type I steroidal drugs (formestane 
and exemestane) which are the mimic of androgen substrates to competitively and irreversibly 
inhibit aromatase enzyme (47). The type II, non-steroidal inhibitors (anastrozole and letrozole) 
mechanistic work by reversibly binds to aromatase enzyme; consequently, it blocks the 
oestrogen biosynthesis from the precursor androgens (47). It is reported to be as effective as or 
superior to TAM for the first-line treatment of metastatic breast cancer (48, 49).  
 
Table 1.2.3.3.1. Adverse drug reactions of anastrozole (50) 
Organ systems Adverse drug reactions of anastrozole 
Cardiovascular Angioedema 
Endocrine & metabolic Hot flash, vaginal haemorrhage, vulvovaginal dryness 
Neuromuscular & skeletal Bone loss and bone fractures, muscle and joint pain, arthritis 
 
 
1.2.4 Resistance to tamoxifen 
Cancer resistance is the pivotal issue for almost all cancer diseases, tamoxifen-resistant 
breast cancer, however, can occur at the first time of tamoxifen exposure (de novo or intrinsic 
resistance) or after the use of tamoxifen treatment for about five to ten years (acquired 
resistance) (51). Most HR positive breast cancer patients (around 70%) favourably respond to 
TAM. However, around 30% of the patients do not respond to TAM after 15 year-time of 
usage. (9, 52). The resistant mechanism of breast cancer can be involved with several 
pharmacological and molecular bases (37). 
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1.2.4.1 Pharmacokinetic issues 
The metabolism of tamoxifen is genetically related to tamoxifen-resistant breast cancer. 
Hepatic metabolisms basically metabolise drugs into more hydrophilicity to promote the 
excretion process (37). However, tamoxifen is the prodrug that required phase I metabolism of 
the liver to biotransform tamoxifen into a more potent metabolite for a therapeutic level (37). 
There are two main hepatic cytochromes P450 isoforms; CYP3A4 and CYP2D6 which 
metabolise tamoxifen into N-desmethyl tamoxifen and 4-hydroxytamoxifen, respectively (37). 
Subsequently, N-desmethyl tamoxifen undergoes the secondary metabolism mainly via 
CYP2D6 while 4-hydroxytamoxifen catalyses mainly through CYP3A4 to form an active 
metabolite called 4-hydroxy-N-desmethyltamoxifen, so-called endoxifen. The binding affinity 
of the metabolites (4-hydroxytamoxifen and endoxifen) to the ER binding site are higher than 
the parent tamoxifen (37). Additionally, the plasma concentration of endoxifen is 5 - 10 times 
greater than tamoxifen (37). Endoxifen and 4-hydroxytamoxifen both are about 100 times more 
potent than tamoxifen in terms of anti-oestrogenic activity (37). Hence, the variation of CYP 
genes, especially the CYP2D6 gene, can promote tamoxifen-resistant breast cancer (53). 
 
1.2.4.2 Cancer stem cells (CSC) 
Cancer stem cells (CSC) are the significant cause of cancer resistance. Breast cancer, 
in particular, can develop resistance and more aggressive leading to therapeutic failure and 
increased mortality in the patients (54). The current therapy can eradicate the bulk of tumours; 
however, the subpopulation of breast cancer stem cells cannot be all eradicated (54). Therefore, 
cancers maintained and differentiated into tumour cells (54). Furthermore, CSC promotes 
breast cancer resistance to the treatment through presumed mechanisms such as enhanced 
renewal ability, anti-apoptosis, and increase efflux pump of anticancer agents (55).  
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1.2.4.3 Loss of ER expression and function 
According to the tamoxifen's mechanism of action, the expression of ER has negatively 
relevant to its activities as of a decrease in ER signalling and function (56). This 
downregulation of ER was the cause for de novo resistance to tamoxifen (56). There was 
reported that around 90% of HR negative breast cancer did not respond to hormonal treatment 
(56). However, most studies identified that hormonal-resistant breast cancer patients have 
expressed ER at the beginning and responded effectively with the treatment; once ER 
downregulation has occurred, cancer cells are not sensitive to the treatment (56). Therefore, 
this indicated that developing resistance of breast cancer to tamoxifen can alter from ER 
positive into ER negative phenotype (56). The downregulation of ER can be identified into two 
significant mechanisms, firstly, the decrease in transcriptional level of ER gene and secondly, 
the population remodelling to produce ER-negative cells from heterogeneous ER positive 
tumour cells (56). 
 
1.2.4.4 Altered expression patterns of coregulatory proteins 
Tamoxifen's mechanisms of action diversely depend on the tissues, for example, in the 
breast, tamoxifen acts as an antagonist, but it has the agonistic action on uterus, cardiovascular 
system, and bone (37). The emphasised mechanism for these actions is the recruitment of 
coregulatory proteins (coactivators and corepressors) which can mediate the ER transcriptional 
activities (37). The well-established coactivator of ER is amplified in breast 1 (AIB1), also 
named as nuclear coactivator 3 (NCOA3), steroid receptor coactivator 3 (SRC3), and thyroid 
hormone receptor activator molecule 1 (TRAM-1) (37). NCOA3 considered being a proto-
oncogene, and more than 30% of breast tumours overexpress; moreover around 5 - 10% of 
breast tumours are genetically amplified (37). 
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Coregulatory proteins compose of the transcriptional complex at the promoter region 
which can drive (coactivators) or block (corepressors) the transcriptional activities of ER-
regulated genes (57). This transcriptional activity is mediated by coregulatory proteins mostly 
represents the ligand-bound ER (57). In breast cancer patients, approximately 60% of the 
tumours express NCOA3 (57). Also, the clinical samples analysis suggested that the 
overexpression of NCOA3 closely related to the non-response of tamoxifen treatment (57). 
The activity of NCOA3 can be regulated via post-transcriptional modifications such as 
methylation, phosphorylation, acetylation, ubiquitination, and sumoylation (58). NCOA3 can 
be phosphorylated at many different positions by several extracellular signalling molecules, 
for example, steroid hormones, growth factors, cytokines, ERK1/2, MAPK, and IKKs (59-61). 
The nuclear receptor corepressor 1 (NCOR1), has also related to tamoxifen-resistant 
breast cancer (62). Tamoxifen-bound ER can recruit the NCOR1 leading to histone-deacetylase 
complexes and repress the ER-regulated genes (63). By knocking down the NCOR1 in breast 
cells, tamoxifen tends to show the agonistic action instead of anti-oestrogenic action (63). 
Therefore, the downregulation of NCOR1 associated with the sensitivity of breast cancer to 
tamoxifen (56, 62-65).  
 
1.2.4.5 Growth factors receptors/kinase signal transduction pathways in 
endocrine-resistant breast cancer 
The ER signalling is a complex network and crosstalk with the many growth factor 
pathways (56). Many downstream molecules of membrane receptor of tyrosine kinases (RTKs) 
such as EGFR, HER2, IGF1R can regulate ER signalling pathways resulting in promoting gene 
expression, cell growth, proliferation, and survival as well as the signalling molecules such as 
farnesyl transferase, mTOR or Raf are also involved in the responsiveness of breast cancer to 
tamoxifen (56). Apart from that membranous ER could stimulate growth factor signalling; in 
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turn, this can also phosphorylate cytoplasmic ER and its coregulator proteins (66). Moreover, 
the phosphorylation of ER structure of serine residues (S118, S168 in particular) at domain 
AF-1 can be activated by the upstream MAPK/ERK1/2 and PI3K/AKT which promote the 
ligand-independent ER function, triggering the transcriptional activity of the genes (67). Also, 
the overexpression of EGFR or activated AKT leads to the phosphorylation of S167 at AF-1 
domain which can enhance the interaction between ER and NCOA3 in the presence of 
tamoxifen (67). Ultimately this interaction caused the resistance of breast cancer to tamoxifen 
(67). The signalling pathways of growth factors promote the phosphorylation of ER, causing 
the resistance of breast cancer. Similarly, many conducted researches showed that the 
overexpression of coactivator NCOA3 related to tamoxifen-resistant breast cancer through the 
phosphorylation of the EGFR/HER2/MAPK-dependent pathway in HER2 overexpressing 
MCF-7 (37). Confirmedly, there was the downregulation of ER expression in transfected 
HER2/ER positive breast cancer cells (37). HER2 is a kind of receptor tyrosine kinase and a 
member of the EGFR family. The overexpression of HER2 interruptedly associated with breast 
cancer phenotype via ER genomic pathways (68).  ER can be phosphorylated at S118 and 167 
at the AF-1 domain by the downstream molecules of HER2 signalling (MAPK and AKT, 
respectively) (68). PI3K/AKT is a significant downstream molecule of the HER2 pathway 
which frequently mutated and be the cause of hormonal-resistant breast cancer (68). PI3K/AKT 
can also activate and stimulate the transcriptional activity of ER regulated genes in both 
oestrogen-dependent and -independent pathways in ER positive breast cancers (68). 
Furthermore, it closely links with cell-cycle progression and cell survival (68).  
Regarding ER positive breast cancer, PI3K-mediated AKT can phosphorylate ERα on 
the ligand-independent pathway (69). Also, AKT can phosphorylate ERβ and trigger the 
transcriptional activity and coactivator recruitment; however, the impact of ERβ on breast 
cancer resistance to anti-oestrogen is rarely understood (70).  The overactivation and 
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overexpression of constitutively active AKT can induce both tamoxifen and fulvestrant 
resistance in an oestrogen-independent pathway, whereas the inhibition of AKT can lead to 
tamoxifen-sensitivity restoration (71, 72). The overactivation of AKT also causes the resistance 
of standard chemotherapy such as doxorubicin (73). Although AKT overexpression was 
suggested to be a significant cause of endocrine resistance of breast cancer, there were studies 
showed that AKT was not upregulation in acquiring resistance to the aromatase inhibitors such 
as letrozole (74-76). Also, this confirmed in both in vitro  aromatase-expressing MCF-7 cell 
line (MCF-7/Ca) and xenografts model (76). 
 
1.2.4.6 Breast cancer resistance protein (BCRP)/ATP-binding cassette 
subfamily G member 2 (ABCG2) 
Breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 
(ABCG2) is an ATP-binding cassette (ABC) transporter (77). It was suggested to be one cause 
of multidrug resistance for various chemotherapeutic drugs as well as targeted therapeutic 
drugs (77). The first discovered of BCRP-caused drug resistance was doxorubicin-resistant 
breast cancer cells (77). BCRP gene transcription was found to be regulated by hypoxia 
inducible factor 1α (HIF1 α), ER, and peroxisome proliferator-activated receptor (PPAR) (78-
80). Apart from that PI3K/AKT signalling played a crucial role in both transcriptional and post-
translational levels of BCRP expression (81, 82). Also, the expression BCRP of both gene and 






1.2.4.7 Nuclear factor kappa-light-chain-enhancer of activated B cells; 
NFκB its role in endocrine resistant breast cancer 
NFκB is one of the majority causes of initiation and progression of many cancers (83). 
Regarding hormone-independent breast cancers, NFκB closely associated with the aetiology, 
progression, and aggressiveness via the mediation of targeted genes such as cyclin D1, 
urokinase-type plasminogen activator (uPA), and C-X-C chemokine receptor type 4 (CXCR-
4)  (84-86). The activity of ER and NFкB was reciprocally antagonism, and many conducted 
pieces of research have suggested that attenuation of ER functions by anti-oestrogens can 
promote NFкB-driven breast tumour progression through driven NFкB transcriptional activity 
(83). On the other hand, inhibition of NFкB activation can downregulate ER expression or 
reduce ER activities and causing the rise of ER-negative or ER-irresponsive cell populations 
that are generally resistant to hormonal therapy (87).  Having said that NFкB and ER negatively 
crosstalk function, many studies indicated that NFкB and ER synergistically transcribed and 
translated genes and proteins that drove in breast tumour aggressiveness such as multidrug 
resistance proteins and prosurvival factors (83, 87). Furthermore, NFкB can also be activated 
through growth factor signalling pathways such as MAPK and PI3K pathways (83). Therefore, 
the crosstalk between NFкB and ER involved MAPK and PI3K were reconciled for hormonal-
resistant breast cancers (83). 
The interaction between ER and NFкB in breast cancer has been the issue of numerous 
studies (88). Overall, the activation silhouettes of both transcription factors of ER and NFкB 
are inversely related (88). In 2000, Biswas et al. demonstrated that activation is found to be 
predominant in ER-negative breast tumours, and directly correlated with the expression of 
ErbB2/HER2 (89). Likewise, several studies have suggested that the levels of NFкB DNA 
binding in breast cancer patients negatively correlated to cellular ER amount and ER target 
gene expression (88, 90). The analysis of gene expression data of all breast cancer molecular 
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subtypes from 78 breast cancer cell lines using the PAM50 algorithm has shown an inverse 
association between the expression of NFкB mediated genes and the ER activity (91, 92). It 
has been confirmed that ER activity and NFкB activity were mechanistically correlated by the 
data from cell line studies and in human tissues (91, 92). In ER positive breast cancers, T47D 
and MCF7 cells experiments showed that Toll-like receptor (TLR) 9-mediated attenuation of 
ER activity, and by adding the NFкB inhibitor BAY11-7082 the activity of ER was reverse 
and the proliferation was increased (93). Also, the study in human retinal pigment epithelial 
cells identified that TLR4 could also mediate the activation of NFкB which will then trigger 
the transcription of NFкB-targeted genes (93). In contrast, with the presence of estradiol (E2), 
the transcriptional activity of TLR4-mediated NFкB activation was inhibited. Admittedly, the 
binding of NFкB to the DNA was prevented by ER (94). Therefore, this showed that the 
inhibitory interaction between the transcription factors of NFкB and ER was reciprocal (94, 
95). The data from Pratt et al revealed that the ER positive/E2-independent MCF7/LCC1 cell 
which derived from ER positive/E2-dependent MCF7 showed the elevation of NFкB activation 
via the withdrawal of E2 induced the DNA binding of NFкB and the expression of Bcl-3, a 
coactivator of  NFкB and also play role as a proto-oncogene to regulate the transcriptional 
activity of NFкB in both in vitro  and in vivo studies (96). Another supported data in 1997 
performed in ER positive-MCF7 breast cancer cell,  human cervical adenocarcinoma (Hela) 
cell, and human osteosarcoma (Saos-2) cells revealed that ER blocked the binding of c-Rel and 
RelA to bind at the promoter of IL-6 (97). Shreds mentioned above of evidence were the 
information of crosstalk between NFкB and ER by inhibition of NFкB DNA binding through 
the interaction of ER with Rel homology domain of NFкB (98).   In microglia cells,  the 
activation of ER also can inhibit RelA nuclear translocation via the ER nongenomic pathways 
through PI3K (98). In MCF7, 17β-estradiol can inhibit the activation of NFкB via increasing 
the level of p105 subunit; consequently, the nuclear translocation of NFкB complex was 
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blocked as the presence of ankyrin repeats at the C-terminus of p105 (99). Interestingly, in vivo 
study in mouse's splenocytes,  the nuclear translocation of all NFкB family members was not 
affected by the ER signalling, but only the harbouring RelA, RelB and c-Rel transactivation 
domain that affected (100). Another crosstalk between ER signalling and NFкB activation was 
the reciprocation of ER with transcriptional activators or repressors, which can lead to a low 
potent induction of NFкB transcriptional activity. In MCF7 and primary osteoblasts, for 
example, ER can compete NFкB to bind to with transcriptional co-activators (such as cAMP 
response element-binding protein, CREB) or ER can recruit co-repressors (such as 
glucocorticoid receptor-interacting protein 1, GRIP1) to NFкB complexes (101, 102). Another 
mechanism linked the negative correlation of the activation of NFкB with the ER signalling 
activation was that the induction of c-Rel activity by protein kinase Cθ (PKCθ) and the 
activated AKT (103). Subsequently, forkhead box O protein 3a (FOXO3a) was activated and 
abated the synthesis of ER (103). The enhancement of zeste homolog 2 (EZH2), a member of 
the polycomb repressor complex 2 (PRC2) and regulates gene expression via trimethylation of 
lysine 27 on histone 3 by TNF-α then trigger the NFкB-dependent signalling (104). Research 
performed in breast cancer showed that silencing EZH2, the ER expression was two-fold higher 
than usual (105-107). This mechanism can imply that NFкB activation could be involved with 
the ER silencing (107). Ultimately, ER expression can be repressed by NFкB (more specifically 






Figure 1.2.4.7.1. Transrepression of oestrogen receptor and NFкB (107) 
 
Evidence confirmed that in  ER positive tamoxifen-resistant breast cancer had a higher 
level of NFκB activity compared to ER positive tamoxifen-sensitive MCF7 (108). Indeed, 
tamoxifen-resistant MCF7 found the hyperactivation of AKT, which increased IкB 
phosphorylation and NFкB DNA binding (109). All in all, the data available for the crosstalk 
of NFкB activity and ER suggested that the activation of NFкB activity affected the sensitivity 
of endocrine/hormonal therapy on ER positive breast cancer cells (107). However, the data on 
the proposed mechanisms and hypotheses of this relationship was still to be clarified. The trans-
repression of ER by NFкB can promote a mechanism of acquired resistance of ER positive 
breast cancer due to the loss of ER expression and function later when the subpopulation of 
tumours cell resistance to the endocrine therapy (107).  This mechanism can also contribute to 
endocrine-resistant breast cancer via growth factor receptor signalling (107). On the other hand, 
trans-repression of NFкB by ER can explain better for the resistance of ER positive breast 
cancer to SERDs, AIs and the withdrawal of oestrogen as the attenuated ER activation (107). 
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This resulted from aromatase inhibition or oestrogen withdrawal can promote the releases of 
NFкB from the ER-mediated inhibition, leading to NFкB-driven tumour progression (107). 
 
1.2.4.8 Cell cycle regulators; CyclinD1 
Cyclin D1 is one of a significant cell cycle machinery contributed to tumour 
progression as well as the progression of ER positive breast cancer (110). Mainly, at the G1 
phase, cyclin D1 plays significant roles in mediates the phosphorylation of tumour suppressor 
Rb through CDK4/6 and sequesters the CDK inhibitors p21 and p27 (111-113). Cyclin D1 is 
one of the ER targeted genes in ER non-classical genomic pathway where the induction of 
cyclin D1 transcription was driven by ER/AP-1 and ER/Sp1 transcription complex bind with 
the SRE segment of the DNA (35). Conversely, anti-oestrogen drugs such as tamoxifen can 
inhibit the expression of cyclin D1 via inhibition of ER signalling (8). Furthermore, AKT is 
also one of the molecules that can indirectly affect the expression of cyclin D1 by 
phosphorylation and inhibition of GSK3β activity, in turn, promote the degradation of cyclin 
D1 (114). Stable overexpression of cyclin D1 in ER positive breast cancer cell led to breast 
cancer resistance to both tamoxifen and fulvestrant (115). Also, breast cancer acquired 
resistance to tamoxifen expressed the upregulation of cyclin D1 (116). Likewise, cyclin D1 
was significant for cell proliferation in tamoxifen-resistant breast cancer and cell cycle 
repression by tamoxifen (117).  
Studies have revealed that there was an upregulation of cyclin D1 in tamoxifen-resistant 
MCF7 overexpressing HER2 (118). Noticeably, crosstalk between cyclin D1 and growth factor 
signalling in hormonal-resistant breast cancer (119). Similarly, overexpression of cyclin D1 
has also led to PAK1 overexpression in tamoxifen-resistant MCF7 (120). As well as 
overexpression of BCAR3 can induce the activity of cyclin D1 promotor found in anti-
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oestrogen resistant MCF7 (121).  Treatment with trastuzumab, a HER2 directed antibody in 
xenografts has downregulated the expression of cyclin D1 and inhibited tumour growth (122).  
Confirmed role of cyclin D1 in clinical endocrine resistance type of breast cancer is 
still developing, in the clinical studies published that around 50% of breast cancer patients 
overexpress cyclin D1 (111, 123). Cyclin D1 amplification was shown to relate with worse 
survival in luminal A and B breast cancer patients and more aggressive cancer in luminal A 
breast cancer patients (124). Also, the high expression of cyclin D1 was associated with 
irresponsive to tamoxifen in breast cancer patients (125). Not surprisingly, decrease the 
expression of cyclin D1 was reported to be a good prognostic marker for breast cancer patients 
(126).   
 
1.2.4.9 Roles of metastasis and angiogenesis in breast cancer: C-X-C 
chemokine receptor type 4 (CXCR4), Hypoxia inducible factor 1 alpha (HIF-1α), 
and Vascular endothelial growth factor (VEGF) 
C-X-C chemokine receptor type 4 (CXCR4), also identified as fusin or CD184, is an 
alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12) 
(127). CXCR4 belongs to the superfamily of the seven-transmembrane domain heterotrimeric 
G protein-coupled receptors displayed on the cell surface of various types of cancer cells,  
including oral cancer, esophageal cancer, gastric cancer, colon cancer, liver cancer, pancreatic 
cancer  thyroid cancer  breast cancer  ovarian cancer, prostate cancer, lung cancer, renal cancer, 
brain cancer, melanoma, and leukemia (128-140). The binding of SDF-1 to CXCR4 can trigger 
various molecular signalling involved in gene transcription, cell survival and proliferation, 
migration, metastasis, angiogenesis, chemotaxis, tumourigenesis, and cancer progression (141, 






Figure 1.2.4.9.1. Potential roles for CXCR4 in breast cancer (143). CXCR4 can be driven its 
transcriptional activity via HIF, resulting in promoting cell proliferation, invasion, and 
angiogenesis in cancer cells.   
 
In breast cancer, the level of CXCR4 expression was very low in breast epithelial cell 
but highly expressed in ductal carcinoma (143). CXCR4 transcription mechanism was related 
to hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2, as the promotor of CXCR4 possessed 
hypoxia response element (HRE) (143). Therefore, HIF can drive the transcriptional activity 
of CXCR4 (143). In normoxia state, Von Hippel Lindau (VHL) degraded HIF protein by 
hydroxylation leading to ubiquitination of HIF resulting in repression of CXCR4 transcription 
and translation (144). In hypoxia state, a lack of VHL (generally occurred in various cancer 
cells) (144). HIF protein was stabilised and translocated into the nucleus which then drove the 
transcription and translation of CXCR4, subsequently CXCR4/CXCL12 pathway was 
activated (144). The stabilised HIF-1α led to the transcriptional activity of HIF-targeted genes 
such as CXCR4 and vascular endothelial growth factor (VEGF), which caused the aggressive 
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breast cancer cells regarding metastasis and angiogenesis (143, 144). Moreover, the expression 
of VEGF can occur during normoxia state and can be upregulated by the HIF-1 independent 
mechanism such as the activation of HER2/Neu and PI3K/AKT pathway through CXCR4  
regulated phosphorylated AKT, in turn, increased VEGF transcription and translation (145). 
VEGF was a crucial angiogenic factor, the level of VEGF in both breast cancer cell lines and 
clinical breast cancer patients related to cancer progression (146). VEGF can promote the 
metastasis of breast cancer cells via two modes of actions; a paracrine mode in which increases 
vascular permeability by mediating rearrangement of actin and changing gap junction resulting 
in enhancing angiogenesis and tumour cell extravasation and an autocrine via stimulation of 
CXCR4 expression  (147).  
According to NFκB related CXCR4 signalling, there was an NFκB binding site located 
at CXCR4 promotor (148). Therefore, when the ligand such as hepatocyte growth factor (HGF) 
stimulated the receptor, p65 and p50 subunit of NFκB then move into the nucleus and bind to 
CXCR4 promotor, stimulating CXCR4 transcription and mediating tumour metastasis and 
invasion (148). The signalling of SDF-1/CXCR4 activated the MAPKs signalling to promote 
chemotaxis and proliferation, induced phospholipase C (PLC)/protein kinase C (PKC)-Ca2+ 
signalling regulated cell migration, and affected PI3K/AKT advancing cell survival. (149, 
150). This shows a positive feedback loop between CXCR4 and the signalling pathways 
mediating tumourigenicity of cancer cells (Figure 1.2.4.9.2) (143). Also, SDF-1/CXCR4 
signalling and EGFR/HER2-neu signalling can promote invasive signs and metastatic growth 











1.3 The galangal compound: 1’ acetoxychavicol acetate (ACA) 
 1.3.1 Background of ACA 
Alpinia galanga (L.) Willd (Zingiberaceae) (greater galangal) is generally known by 
several names such as galangal, greater galangal, Java galangal and Siamese ginger (154). They 
were generally used as a cooking spice, especially in Thai and Indonesian cuisine. In the past, 
galangal has been used to address many diseases, such as eczema, bronchitis, and stomach 
disorder (155). 1’ Acetoxychavicol acetate (ACA), C13H14O4 is a natural compound from 
rhizomes and seed of the ethnomedicinal plant A. galanga (156). The molecular weight of ACA 
is 234.25 g/mol and the density is 1.122 g/cm3. The rhizome of A. galangal was edible and was 
popular in terms of herbal medicine in Southeast Asia (157). Galangal contained abundant 
flavonoids and volatile oils, and different parts of galangal possessed distinct pharmacological 
activities (157). The critical part provided major bioactive compounds for galangal was the 
rhizomes which were reported to have antimicrobial activity, anti-oxidative effect, 
immunostimulant and expectorant action (158). Natural ACA possessed structure-activity 
relationships (SARs) in two key features as its pharmacophore, which were the para 
substitution of the 1’ -acetoxyl group at the benzene ring and linear ethyl and propyl chain 
carbonates (159). 
 
Figure 1.3.1. Structure of ACA (from Palitapongarnpim et al (160)). The structure shows the 
pharmacophore of ACA which consists of the 1’ -acetoxyl group and ethyl- and propyl- chain 
carbonates. 
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1.3.2 Roles of ACA in cancers 
ACA has been reported the anti-oxidant and anti-inflammatory activities in many 
studies (161). It showed the capability to block the accumulation of cellular lipid due to the 
downregulation of PPARγ and C/EBPα and promote the phosphorylation of AMP-activated 
protein kinase (AMPK) in rat xenograft model  (161).  Regarding growth inhibitory effects, 
ACA can induce the accumulation of tumour cells in the G1 phase resulting in the 
downregulation of phosphorylated Rb, an increase of total Rb, and a decrease of 
phosphorylated  p27kip1 (162).  
ACA exhibited cytotoxic activity in various tumour cell lines, which were MCF7, 
HepG2, oral squamous carcinoma (HSC-2 and HSC-4), and epidermoid cervical carcinoma 
(CaSki) with IC50 value range between 5 and 50 µM with no toxicity to normal human 
mammary epithelial cell (HMEC) cell tested up to 80 µM (163). Tumour cells were all dead 
via apoptosis after 30 hours using  40.0 µM detected by flow cytometry analysis of annexin-V 
and PI co-staining (163).  
In term of antiproliferative activity, ACA reported to have antiproliferation in four 
myeloid leukemic cell lines (NB4, UF-1, HL-60, and K562,) (164). ACA induced apoptosis as 
well as the impairment of mitochondrial transmembrane potential (ΔΨm) and activation of 
caspase-9, consequently activated death signalling through mitochondrial oxygen stress 
pathway in NB4 cell (164). While the apoptotic induction of ACA in HL-60 cell caused by 
DNA fragmentation, caspase-3 activation, and PARP cleavage (165). Also, ACA has been 
reported the apoptotic induced antitumour activity in other cancer types such as Ehrlich ascites 
tumour cells (EATC), and hepatocellular carcinoma cells (HepG2) (166, 167). ACA can trigger 
the activity of caspase-8 subsequently activated the Fas-mediated apoptosis (164). 
Furthermore, in vitro and in vivo study of  ACA in multiple myeloma cells showed that ACA 
provided growth inhibition via apoptotic induction through the repression of anti-apoptotic 
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proteins' expression, activation of caspase-8, and inhibition of NFκB activation (156). ACA 
can induce the activities of caspase 3, 9, and 8 and induced GO-G1 phase cancer cell arrest in 
myeloma cells (156). This suggested that ACA-induced apoptosis in myeloma cells mediates 
both mitochondrial- and Fas-dependent signalling (156).  Moreover, ACA can inhibit the 
phosphorylation of amino acid serine and promote the degradation of IκBα (156). The study in 
RPMI8226 cells showed that the nuclear expression of NFκB was blocked by ACA, resulting 
in the accumulation of cytosolic NFκB (156). The mode of ACA action through the inhibition 
of nuclear expression of NFκB was consistent in RPMI8226-grafted NOD/SCID mice and the 
result from RPMI8226 cell line (156). Also, the result has shown that ACA has significantly 
decreased tumour weight in ACA treatment group compared to control group, ultimately all 
these information has led to confirm that ACA possessed the inhibitory effect on NFκB and 
induced apoptosis in myeloma cells both in vitro  and in vivo studies (156). Further 
investigation of In and colleagues in 2005 showed that the mechanism of ACA on apoptosis 
induction in RPMI8226 was related to the up-regulation of both TNF-related apoptosis-
inducing ligand/Apo2 ligand (TRAIL/Apo2L) (168). 
ACA treatment in oral squamous cell carcinoma (SCC) showed the antiproliferation, 
apoptosis induction and antimigration without causing toxicity to HMEC cell (169). 
Combination of ACA with cisplatin showed a synergistic cytotoxic effect indicated by using 
combination index studies (169). ACA alone also suppression of IKK/β activation 
consequently inhibited the constitutive activation of NFκB (169). Human oral tumour mice 
xenografts studies revealed that ACA alone was as effective as in combination with cisplatin 
in decreasing tumour volume with minimal bodyweight loss and further potentiated cisplatin 
outcomes when used in combination (169). The effects of ACA also associated with a down-
regulation of NFκB regulated genes (FasL and Bim), covering pro-inflammatory (NFκB and 
COX-2) and proliferative (cyclin D1) biomarkers in tumour tissue (169). 
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Another study of ACA demonstrated that ACA had a time- and dose-dependent 
cytotoxicity to both MCF7 and MDA-MB-231 at the concentration tested at 10 - 50 µM (170). 
ACA showed a dominant mode of action through the suppression of RANKL-induced NFκB 
activation in a time- and concentration-dependent manner and blocked the osteoclastogenesis 
induced by MCF7, multiple myeloma MM1 cells, and head and neck squamous cell carcinoma 
LICR-LON-HN5 cells (171). This results showed that ACA might have a beneficial action for 
osteoporosis and cancer-related bone deterioration (171).  ACA was also reported the  
antimigration/invasion and antimetastasis effect in the concentration vary from 5-40 µM from 
the results of in vitro matrigel invasion assay and skeletal metastasis in breast cancer mouse 
model (172). ACA had cytotoxic effects and antimigration and mechanistically worked through 
the suppression of constitutive and interleukin-6-inducible STAT3 activation and decreased 
the accumulation of nuclear STAT3 as well as DNA-binding activity of STAT3 (172). 
Moreover, ACA treated cells had a higher amount of Src homology region 2 domain-containing 
phosphatase 1 (SHP-1) and inhibited STAT3 signalling resulting in the repression of STAT3 
regulated genes such as matrix metalloproteinase (MMP)-2 and -9 which responsible for cell 
migration and invasion (172). This led to the conclusion that ACA inhibited cancer cell 
migration via SHP-1/STAT3/MMPs signalling pathway (172). In mouse macrophages (RAW 
264.7) cells using LPS to induce cyclooxygenase (COX)-2 mRNA expression, the activation 
of MAPK,  p38, ERK1/2, JNK1/2 and AKT, and the degradation of the IκB-α protein and 
nuclear translocation of NFκB p65 subunit revealed that ACA can abrogate ERK1/2 and 
JNK1/2 as well as the activation of AP-1, NFκB, and CREB transcription factors (173).  
 The dominant published mechanism of ACA was the inhibition of NFκB activation 
which caused by many ligands and substances such as TNF, IL-1β, PMA, LPS, H2O2, and 
doxorubicin (171). Regarding the inhibition of NFκB activation, ACA did not interfere with 
the DNA binding activity of NFκB (171). Instead, ACA inhibited the translocation of p65 
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subunit by blocking the activation of IκBα kinase, IκBα phosphorylation, IκBα degradation, 
and p65 phosphorylation (171).  ACA also inhibited NFκB-dependent gene expression 
stimulated by TNF, TNFR1, TNFR-associated death domain protein, TNFR-associated factor-
2, and IκBα kinase, but not that stimulated by p65 (171). ACA suppressed the expression of 
TNF-induced NFκB-mediated proliferative genes (cyclin D1 and c-Myc), antiapoptotic genes 
(survivin, inhibitor of apoptosis protein-1 (IAP1), IAP2, X-chromosome-linked IAP, Bcl-2, 
Bcl-xL, Bfl-1/A1, and FLIP), and metastatic genes (COX-2, ICAM-1, VEGF, and MMP-9) 
(171). Therefore, ACA exhibited the ability to induce apoptosis and inhibit invasion via 
inhibition of NFκB activation and NFκB-targeted genes involved in cell proliferation, 
metastasis, and apoptosis (171). ACA suppressed VEGF-induced proliferation, migration, 
adhesion and tubulogenesis of HUVECs in a dose-dependent manner (174). In Matrigel plugs 
vasculature formation assay, ACA inhibited VEGF-induced microvessel growing from aortic 
rings and suppressed new vessel formation. In vivo study confirmed the mechanism of 
inhibition of VEGF by ACA through blocking the activation of VEGF-mediated Src kinase, 
FAK and Rho family of small guanosine triphosphatases (GTPases) (Rac1 and Cdc42, but not 
RhoA) (174). In human prostate cancer cells (PC-3), the treatment of ACA at 5-50 µM 
decreased cell viability and abolition of angiogenic factor by interfering with dual Src/FAK 
kinases. In a PC-3 xenograft model, ACA (6 mg/kg/day) significantly inhibited the level of 
Src, CD31, VEGF and Ki-67 as well as tumour weight and volume  (174). ACA inhibited 
glioblastoma cell proliferation as a result of promoting apoptotic cell death by enhancing the 
activities of caspase 3 (175). ACA notably diminished the migration of glioblastoma cells by 
lowering their adhesive functions (175). Additionally, ACA increased the protein expression 
of the pro-survival signalling cytokines, IL-6 and IL-1α which compensated pro-survival 
response in addition to pro-apoptotic ACA-induced caspase 3 response (175).  
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Ohnishi and team (1996) performed the xanthine oxidase inhibitor effect of ACA on 4-
nitroquinoline 1-oxide (4-NQO)-induced oral carcinogenesis in male F344 rats (176). The 
result showed that ACA administration group significantly reduced tongue polyamine levels 
(35-40% inhibition) (176). These results evidenced that ACA inhibited rat oral carcinogenesis, 
and such inhibition might be associated with suppression of cell proliferation in the oral mucosa 
by the xanthine oxidase inhibitor (176). In 1997,  Tanaka and colleagues performed in vivo 
investigation of the effects of ACA to inhibit the development of azoxymethane-induced colon 
carcinogenesis (177). They reported that ACA suppressed cell proliferation in the colonic 
mucosa and its induction of glutathione S-transferase (GST) and quinone oxidoreductase 1 
(NQO1) (177). Further in vitro  study of ACA  in rat intestinal-epithelial cells (IEC6) showed 
that ACA-induced glutathione S-transferase (GST) and NAD (P)H: quinone oxidoreductase 1 
(NQO1) activities, increased intracellular glutathione (GSH) level, and upregulated 
intranuclear Nrf2 and cytosolic p21 (178). Impliedly, that activation of phase II enzymes via 
Nrf2 related to p21 is a possible mechanism of ACA to halt the advance of carcinogenesis 
(178). In Ehrlich ascites tumour cells, ACA showed the decrease in the intracellular GSH 
levels, suggesting that ACA-induced reduction of the cellular GSH levels can lead to growth 
arrest of the cancer cell (179). 
ACA can also modulate the expression of miRNAs in cervix carcinoma cells (Ca Ski, 
HeLa); therefore, tumour suppressor miRNAs miR-138, miR-210 and miR-744 were 
upregulated (180). In 2013, there was a study reported that ACA significantly inhibited the 
growth of human head and neck squamous cell carcinoma cell line HN4 and induced cell 
apoptosis (181). Additional studies indicated that ACA (17.70 µM) downregulated the 
expression of miR-23a in HN4 cells which associated with phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN), a target of miR-23a (181). In human non-small cell lung 
cancer (NSCLC), ACA showed cytotoxicity and induced formation of cytoplasmic vacuoles 
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(182). Moreover, ACA has been shown its action on the induction of pro-autophagy pathway 
through Beclin-1-independent pathway in NSCLC (182). In cervical cancer, it has been stated 
that ACA targeted decapentaplegic homolog 4 (SMAD4) resulting in down-regulation of miR-
210 expression, which commonly overexpressed in cervical cancer (183). 
ACA has been reported to inhibit the proliferation of a broad range of cancer types in 
both in vitro and in vivo studies, including bile duct cancer, oesophageal cancer, large intestinal 
cancer, oral cancer and hepatocellular carcinoma (176, 177, 184-186). ACA induced apoptosis 
in myeloma cells through the inhibition of NFκB-related functions and also inhibited the 
phosphorylation of inhibitor of nuclear factor kappa B kinase subunit alpha/beta (IKKα/β) 
leading to the suppression of NFκB activation in human squamous carcinoma (HSC-4) cells 
(169, 187). Furthermore, the effect of ACA on myeloma cell can induce apoptosis as well as 
inhibited ERK MAPK signalling pathway (188). Also, ACA has been reported to repress 
tumour volume and weight, Proto-oncogene tyrosine-protein kinase (Src), Cluster of 
differentiation 31 (CD31), proliferative marker Ki-67, and blocking the activation of Vascular 
endothelial growth factor (VEGF)-mediated Src kinase in vivo (174). In MCF7 and MDA-MB-
231 cell lines, ACA has revealed to be apoptotic induction agent via c-Jun N-terminal kinase 





1.3.3 Proposed mechanism of action of ACA on endocrine resistant breast cancers 
Crosstalk between the NFκB pathway and endocrine therapy resistance in breast 
cancers has been established (189). Also, it has been shown that MCF7/LCC9 cells (ER-
positive, oestrogen-independent, and anti-oestrogen (tamoxifen and fulvestrant) cross-
resistant) and MCF7/RR cells (ER-positive, oestrogen-independent for growth, tamoxifen-
resistant and fulvestrant-sensitive) have higher p65 basal levels compared to MCF7 cell (ER-
positive and anti-hormone sensitive) (190). Increased expression of p65  in endocrine-resistant 
breast cancer cells may be involved in promoting cancer cell growth (190). Also, the 
enhancement of NFκB and AP-1 transcriptional activities were reported in endocrine-resistant 
breast cancer cells (191). Treatment of the endocrine-resistant breast cancer cells with 
pathenolide (NFκB inhibitor), significantly decreased the transcriptional activity of NFκB 
regulated genes compared to MCF7 cells (190). This evidence shows that inhibiting NFκB 
pathway results in the inhibition of proliferation and NFκB transcriptional activity in both of 
the resistant cell lines, compared to MCF7 control cells. 
ACA, as a potent NFκB inhibitor through inhibition of nuclear translocation of the p65 
subunit and its effects on the repression of AKT and ERK1/2 activity (171, 173, 192) could 
inhibit endocrine-resistant breast cancer cell growth, and other related effects. 
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1.3.4 Safety profile of ACA 
 ACA has been studied the safety both in vitro  and in vivo as revealed in the study of 
Awang and partners (2010) which showed that ACA at the concentration range up to 80 µM 
had no adverse cytotoxic effects on normal dermal microvascular endothelium (HMEC cells) 
(163).  Also, in human oral tumour xenografts, studies in mice revealed that ACA alone was 
as effective in reducing tumour volume without any toxicity (169). In 2000, Moffatt et al. 
demonstrated that ACA had no cytotoxic effect on normal rat hepatocytes at increasing 
concentration up to 40 µM (166). Furthermore, ACA (3 mg/kg) had been shown no toxic effects 
in vivo in a nonobese diabetic/SCID mice leukaemia model (164). 
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1.4 The zebrafish model 
Danio rerio is a vertebrate and a non-mammalian specie that commonly used in 
developmental process and human diseases including, gastrointestinal disorders, brain 
disorders, muscle disease, and cancers (193-197). Zebrafish xerograft model is increasingly 
used in cancer research as a screening model, particularly with tumour proliferation, 
angiogenesis, metastasis, and antineoplastic drug screens (198). Around 70% of all human 
disease genes are functional homolog with zebrafish specie (199). The advantages of zebrafish 
for using as an animal experiment are its transparency of embryos and embryonic development 
(200). Therefore, it can significantly aid imaging and protein/cell marker tracking to observed 
biological and disease processes (200). In addition, it gives high number of offspring for each 
breeding under laboratory conditions, and allowing high confidence in statistical analysis (201, 
202). Also, zebrafish models are easy-manipulated method and allow real-time visualisation of 
tumour mass and volume (203). Zebrafish xenotransplantation is the superior transplantation 
model in avoiding the issue of graft rejection compared to mouse models (203, 204). In mouse 
models, the aspect to avoid graft rejection is to use the genetically modified mouse by 
immunosuppression of T, B, and natural killer cells, NOD/SCID mouse (205). Unlike in 
zebrafish, their innate and adaptive immunity are not fully functioned until 21 days of life 
(204). At this stage, their T and B cells enter thymus and processing the immune maturation 
(204). The absence of the immune system until 3 to 4 days post fertilisation (dpf) giving the 
benefit of unnecessary usage of immunosuppressants in zebrafish engrafted humanised 
tumours (206). Thus, this model is favourable and convenient in xenotransplantation 
experiments (206). 
Zebrafish is well-established for various cancer studies such as breast cancer, prostate 
cancer, liver cancer, glioblastoma, and melanoma (207-210). It has been used for studying the 
tumour microenvironment of tumour-induced angiogenesis and tumour neovascularisation in 
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tumour growth and metastatic stage (211). In breast cancer, it has been suggested that zebrafish 
has possessed the oestrogen-responsive genes and signalling pathways (212). Furthermore, 
zebrafish has highly conserved of oestrogen-responsiveness, which responsible for cell 
proliferation, DNA damage, and cell death (212). Therefore, this model can potentially be used 
in oestrogen-dependent research (212). Additionally, zebrafish model has been used in triple 
negative breast cancer (TNBC) type to investigate epithelial-mesenchymal transition (EMT) 
through β1 integrin mediated transforming growth factor-β (TGF-β) pathway (213). Also, 
zebrafish has been used in TNBC xenograft metastatic model and micro-metastatic formation 
through the CXCR4-CXCL12 signalling axis to project the new pharmacological therapy for 
TNBC (214, 215).  
With all striking genetic information of zebrafish models, it promotes the utilisation of 
zebrafish in the physiopathology of human diseases (216, 217). Also, this model benefits for 
the studying of promised therapeutic compounds in terms of efficacy, safety, and mechanism 
of action in various classes of disease researches (218). 
 
1.5 Molecular Docking Simulation 
The molecular docking approach was a computational tool, which commonly used for 
target identification (219). This approach can identify protein targets (e.g. receptors, ligands) 
of the pharmacologically active substances (219, 220).  It can be used as a high throughput 
screening for structured-based lead optimisation in the drug discovery process (220, 221). 
There are several processes to perform molecular docking approach (222). The processes are 
composed of two main methods, which are the preparation of ligand and receptor (222). The 
preparation of ligand method includes generation, optimisation, and analysis of ligand’s 3D 
structure (222). In addition, the Protein Data Bank (PDB) is the primary source for the 3D 
structure of proteins, protein fragments, nucleic acids, and protein-ligand complexes (222). 
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This well-established source is used for analysing the proteins' structure or comparing any 
protein structure  (222). The receptor preparation is performed by using the rigorous target 
protein conveying a single conformation of the receptor (222).  
This docking technique is also used for predicting and matching the ligand to the protein 
binding site (223). It is noted that the protein-ligand binding interaction is a key for molecular 
signal transduction and biological mechanism of action (223, 224). One of the most significant 
points is the versatility of molecules involved in the complex molecule (225). These molecules 
include both the target macromolecule (typically proteins) and the ligand (225). Typically, the 
rationale for drug development is to evaluate the compound capable of inhibiting the 
functioned protein responsible for diseases progression (225). On the one hand, is to fill the 
gap to find the organic compound work as a selective inhibitor (226). From the aforementioned, 




1.6 Research question 
 - Does ACA inhibit proliferation, migration/invasion, and angiogenesis in endocrine-
resistant breast cancer cells? 
  - Does ACA inhibit the expression or activity of HER2, NCOA3 and PI3K/ AKT or 
ERK1/2 and suppress NF-κB targeted genes involved in endocrine-resistant breast cancer 
cells?   
   - Does ACA inhibit proliferation of endocrine-resistant breast cancer cells in zebrafish 
xenograft model? 
 
1.7 Objectives of the study 
ACA is a promising compound, prominently for its anticancer attributes through 
inhibition of NF-kB activation; it may implement a new option in breast cancer therapeutics. 
This study aims to investigate the effects of ACA on hormonal-sensitive breast cancer (MCF7) 
and hormonal-resistant breast cancer cells (MCF7/LCC2 and MCF7/LCC9) to unpack the 
signalling pathways that are affected by ACA. Therefore, this study focuses primarily on the 
effects of ACA on the inhibition of NF-kB targeted genes which involved in breast cancer cell 
proliferation (Cyclin D1; CCND1, MYC proto-oncogene; c-Myc), invasion (C-X-C chemokine 
receptor type 4; CXCR4, urokinase plasminogen activator; uPA), angiogenesis (VEGF, Basic 
fibroblast growth factor 2; FGF2). Subsequently, the in vivo antiproliferative activity of ACA 
in MCF7/LCC9 grafted zebrafish xenograft model. Additionally, the signalling mechanisms of 
ACA via the growth factor receptors including HER2 and its downstream molecules such as 
MAPK/ERK1/2 and PI3K/AKT. Also, the effect of ACA on the abolishment of NCOA3 
transcriptional activity and protein expression since NCOA3 the important co-activator of ER 
and is phosphorylated by ERK1/2. Therefore, the expression of NCOA3 protein could be 
altered by the effect of ACA. 
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1.8 Hypothesis 
- ACA exhibits its antiproliferation effects through inhibition of HER2, NCOA3, AKT, 
and ERK1/2 which are key molecules involved in endocrine-resistant breast cancer cells. 
- ACA inhibits the mRNA expression of NF-κB targeted genes which are reported to 
be overexpressed in endocrine-resistant breast cancer namely, proliferative factors (CCND1, 
C-myc), invasive factors (uPA, CXCR4), angiogenic factors (VEGF, FGF2).  
- ACA inhibits proliferation of endocrine-resistant breast cancer in zebrafish xenograft 
model. 
1.9 Experimental design 
 The experiment is divided into four parts: Isolation and purification, in vitro anticancer 












2.1 Cell lines and its characteristics 
The human ER positive breast cancer (Michigan Cancer Foundation-7; MCF7) 
(American Type Culture Collection (ATCC®) HTB-22™) cell line was purchased from ATCC, 
USA. The tamoxifen-resistant breast cancer (MCF7/ Lombardi Cancer Center 2; LCC2) and 
tamoxifen/fulvestrant-resistant breast cancer (MCF7/LCC9) cell lines were obtained from Dr. 
Robert Clarke (Georgetown University Medical center, Washington DC, USA).  
The MCF7/LCC2 and MCF7/LCC9 cells are sublines of the ovarian-dependent human 
breast cancer cell line MCF7  (228). These cell lines were established after isolation from one 
of three small, slowly-proliferating MCF7 tumours in vivo in ovariectomised-athymic nude 
mice (MIII) after 6 months of inoculation (229). The initial MCF7/MIII line was further 
passaged in ovariectomised nude mice and re-established in vitro as the continuous cell line 
MCF7/LCC1 (ovarian-independent) (230). The baseline level of oestrogen receptor was 
equivalent in MCF7/MIII, MCF7/LCC1, and MCF7 (230). The basal level of oestrogen-
regulated pS2 mRNA was evaluated and shown to be higher in MCF7/MIII and MCF7/LCC1 
compared to the parental MCF7 cell (230). The ovarian-independent breast cancer cells 
(MCF7/MIII and MCF7/LCC1) showed higher sensitivity to oestrogen, which was associated 
with elevation of  the expression of progesterone receptor (229). 
The oestrogen-independent MCF7/LCC2 (tamoxifen-resistant) cell line was derived 
from the oestrogen-responsive MCF7/LCC1 after continuous exposure to 10-6M of 4-
hydroxytamoxifen for 5 years (231). MCF7/LCC2 is still sensitive to the inhibitor, ICI 182,780 
(fulvestrant) similar to MCF7 cells (231). MCF7/LCC2 cell line was reported to have 
expression of basal progesterone mRNA level comparable to parental MCF7 cell (232). The 
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MCF7/LCC9 cell line was derived from MCF7/LCC1 after continuous exposure to ICI 182,780 
(fulvestrant), and showed cross-resistance to tamoxifen, although these cells have never been 
exposed to the drug (228). MCF7/LCC9 cell line was reported to have higher baseline mRNA 
level of progesterone receptor compared to parental MCF7 cell (228).  
 
Figure 2.1.1. The derivation of MCF7 sublines MCF7/LCC2 and MCF7/LCC9 (228) 
 In this study MCF7/LCC2 and MCF7/LCC9 were selected for use as  representatives 
of the most common oestrogen receptor-positive breast cancer cells which have developed 
resistance to hormonal therapy post-treatment, and hence relevant to endocrine-resistant breast 
cancer patients. In our lab, routine confirmation of the resistance of cell lines was performed 
using real-time qPCR to determine the expression of genes involved in endocrine-resistant 




0.4% Trypan blue dye (Sigma, USA) 
1’ Acetoxychavicol acetate (ACA) isolated from fresh Alpinia galanga rhizomes    
4-Hydroxytamoxifen (Sigma, USA) 
5-Bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma, USA) 
96–well, 24–well,  6–well plates (Corning, USA) 
Acetone (Sigma, USA) 
Alkaline phosphatase (AP) buffer (Sigma, USA) 
Autopipette (Gilson, USA) 
BD matrigel matrix (Biosciences, USA) 
Biohazard laminar flow hood (ESSCO, USA)  
CellTracker™ CM-DiI Dye (Thermo Fisher, US) 
Centrifuge (Hettich, USA) 
Charcoal strip fetal bovine serum (Gibco, USA) 
Crystal violet (Sigma, USA) 
Deuterochloroform (CDCL3) (Sigma, USA) 
Diethyl pyrocarbonate (DEPC) (Molekula, UK) 
Dimethyl sulfloxide (DMSO) (Sigma, USA) 
Dulbecco’s modified eagle’s medium (DMEM) (Gibco, USA) 
Ethyl acetate (Sigma, USA) 
Fetal bovine serum (FBS) (Gibthai) 
Forceps 
Fresh Alpinia galanga (L.) Willd rhizomes 
Fourier Transform Infrared (FTIR) spectrometer (PerkinElmer, USA)  
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Gel electrophoresis (Bio-Rad, USA)  
Hemocytometer (Brand, Germany) 
Hexane (Sigma, USA) 
ImProm-IITM Reverse Transcription system (Promega, USA) 
Improved MEM (Gibco, USA) 
Insulin, Human recombinant (Gibco, USA)  
Light microscope (Nikon, USA) 
Matrigel invasion chambers (Corning USA)  
Micromass LCT mass spectrometer (Waters, USA) 
Minimum Essential Medium (Gibco, USA) 
Methanol (MeOH) (Sigma, USA) 
Methylthiazolyldiphenyl- tetrazolium bromide (MTT) (Sigma, USA) 
NanoDrop™ One/OneC Microvolume UV-Vis Spectrophotometer with Wi-Fi (Thermo Fisher, 
US) 
Nitro blue tetrazolium (NBT) (Sigma, USA) 
Non-essential amino acids (NEAA) (Gibco, USA) 
Nuclear Magnetic Resonance (NMR) spectrometer AV500 (Bruker, USA) 
Penicillin/streptomycin (Hyclone, USA)  
Phenylthiourea (PTU) (Sigma, USA) 
Phosphate-Buffered Saline/Tween-RNAse (PBST-RNAse) (Sigma, USA) 
Polysorbate 20 (Tween 20) (Sigma, USA) 
Potassium chloride (KCl) (Sigma, USA) 
Primers (Bio Basic, Canada) 
Promega GoTaq™ qPCR Master Mix (Promega, UK) 
Promega ImProm-II™ Reverse Transcription (Promega, UK) 
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Spectrophotometer (Shimadzu, Japan) 
Sodium chloride (NaCl) (Sigma, USA) 
T-25 and T-75 tissue Culture flasks (Corning, USA)  
Taq polymerase (Vivantis, USA) 
Tetramethylsilane (TMS) (Sigma, USA) 
Thermocycler machine (Eppendorf, USA) 
TLC silica gel 60 F254 (Merck, USA) 
Tricaine methanesulfonate (MS222) (Sigma, USA) 
TRiZol reagent (Invitrogen, UK) 
UV-Vis Spectrophotometer, UV-1800 (Shimadzu, Japan) 
Vortex mixer (Scientific industries, USA)  
Zinc solution (Gibco, USA) 
Zebrafish apparatus 
• Eppendorf FemtoJet 4i (Eppendorf, UK) 
• G-100/100L Thin-walled glass capillary (Narishige, Japan) 
• Handmade hair-inserted glass capillary loop 
• Leica stereo microscope S9i (Leica, UK) 
• Nikon microscope camera (model DS-Ri2) (Nikon, US) 
• Nikon stereo microscope SMZ18 (Nikon, USA) 
• P-1000 Micropipette puller (Sutter Instrument Company, USA) 
• Pneumatic Microinjector IM300 (Narishige, Japan) 
• Zebrafish Housing (ITS-Z) (IWAKI Aquatic, USA); additional information can be 




2.3.1 Preparation of crude extract and purification of 1’-acetoxychavicol acetate 
(ACA) 
The fresh A. galanga (L.) Willd rhizomes were collected locally in Bangkok, Thailand 
(November 2017). The plant was identified by Dr. Thanapat Songsak (Department of 
Pharmacognosy, College of Pharmacy, Rangsit University, Thailand). A voucher specimen 
number was CP-Ag-29 and the specimen was placed in the College of Pharmacy, Rangsit 
University, Thailand.   
 
Figure 2.3.1.1. The rhizome of greater galangal. The figure shows fresh rhizomes of 
A. galangal.  
The fresh A. galanga rhizomes (10.0 kg) were chopped to increase the surface area for 
performing cold extraction using hexane as an extraction solvent. The crude extract in hexane 
was prepared from raw material by cold percolation for 5 minutes. The process of extraction 
was repeated three times with hexane. The hexane extracts were combined and concentrated 
under vacuum at 40 °C and pooled together to obtain 7.2 g of brown oily substance (crude 
hexane extract). After that crude hexane extract was initial screened by performing spot thin 
layer chromatography (spot TLC) with the condition of Hexane 8 : Ethyl acetate 2 was 
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performed and followed by UV detection using  UV-Vis Spectrophotometer SHIMADZU, UV-
1800 of spot TLC of ACA at the wavelength 254 nm.  
After that crude hexane extract (7.2 g) was chromatographed on silica gel glass column. 
This was eluted with stepwise gradient of hexane-acetone. The fraction (hexane 85 : acetone 
15) was collected separately and concentrated in a vacuum at 40 °C. The yield of pure 1’ 
acetoxychavicol acetate (ACA) after process through column chromatography was 6.5 g and 
will be used for further analysis and for the study of anticancer activities.  
 
2.3.2 Analytical procedures 
To identify the bioactive compound in the column chromatographic fraction (hexane 
85 : acetone 15). This fraction was responsible for cytotoxic activity and was further subjected 
to characterisation of bioactive compound ACA (233, 234). 
Proton nuclear magnetic resonance (1H NMR) and carbon thirteen nuclear magnetic 
resonance (13C NMR) experiments were carried out on a Bruker AV500 NMR spectrometer, 
operating at 500 MHz for hydrogen and carbon and then recorded in CDCl3 with 
tetramethylsilane as an internal standard. Electrospray ionization (ESI)/Time-of-Flight (TOF) 









2.3.3 Maintenance of MCF7, MCF7/LCC2, MCF7/LCC9, and PCS201-010 cell 
lines 
ER positive (MCF7), tamoxifen-resistant (MCF7/LCC2), and tamoxifen/fulvestrant-
resistant (MCF7/LCC9) cell lines were cultured on 25-cm2 flasks with MEM (minimum 
essential media) medium with 5% fetal bovine serum (FBS), 100 U/ml penicillin and 100 U/ml 
streptomycin, and incubated at 37°C in humidified air and 5% CO2. While the normal neonatal 
fibroblast (PCS201-010) cell line was culture in DMEM (Dulbecco's Modified Eagle Medium) 
high glucose and supplement with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 
U/ml streptomycin. Culture medium was changed every 48 hours to assure that essential 
nutrition was available to the cells. For further experiments, MCF7, MCF7/LCC2 and 
MCF7/LCC9 cell lines were sub-cultured at 85-100% confluency by using trypsin-EDTA 
(Ethylenediaminetetraacetic acid) mixture to detach cells from the coated plate surface and 














2.3.1 In vitro studies 
2.3.1.1 Viability assay 
The cytotoxic activity of 1’ acetoxychavicol acetate in MCF7, MCF7/LCC2, and 
MCF7/LCC9 cells was assessed by the (methylthiazolyldiphenyl–tetrazolium bromide assay) 
MTT assay. 
Cell viability/cytotoxicity was determined by a modified MTT assay as previously 
described (235) Cells (5 × 105 cells/mL) were seeded into each well of a 96-well plate and 
incubated for 24 hours. The cells were exposed to ACA at 0 - 60 µM for MCF7, MCF7/LCC2, 
and MCF7/LCC9 cells. While the PCS201-010 cells were treated with ACA for toxicity test at 
the concentration up to 320 µM. Tamoxifen (0 - 20 µM) was used as a positive control for 
MCF7 cells. Palbociclib (0 - 20 µM) was used for MCF7/LCC2 and MCF7/LCC9 cells. The 
negative control/vehicle control used in the study was 0.1%v/v ethanol (0.1% EtOH) in 
completed medium. In addition, this study was also performed the effects of vehicle control on 
untreated control (completed medium). All cell lines were treated and incubated with 3-time 
points; 24 hours, 48 hours, and 72 hours. Following the treatment incubation time, the medium 
was then replaced by MTT (final concentration 0.5 mg/mL) and incubated for a further 4 hours 
at 37°C. The purple formazan crystals were dissolved in DMSO. The relative number of viable 
cells was assessed by measuring the absorbance of the formazan product at 570 nm with a 
microplate reader (BioTek Synnergy, USA). After the initial exploratory experiments, the MTT 
assay was performed in triplicates for each cell line with ACA concentrations ranging from 0 
- 60 µM for the determination of IC50. All the work was repeated in three independent 
experiments. 
The calculation of the percentage cell viability as shown below:  
 Mean absorbance obtained from treated cells x 100 
 Mean absorbance obtained from untreated cells  
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The half inhibition concentration (IC50) from 48 hours incubation and diluted for other 
two concentrations as twofold dilution (IC25 and IC12.5) will be used for further studies.  
In the in vitro viability test, there were two positive controls have been used for the 
study. 4OH-Tam was used as a positive control for MCF7 cell while palbociclib was used for 
MCF7/LCC2 and MCF7/LCC9 as these two cell lines were resistant to hormonal treatment in 
which palbociclib was recommended for clinically used as combination with endocrine therapy 
in ER positive advanced breast cancers (236).   
ACA could have different potency for each cell line. Therefore, the concentration used 
for further studies was very critical in terms of the accuracy and precision of the data. In all 
gene and protein analysis studies, all cell lines were incubated with ACA for 24 hours. 
However, the IC50 at 48 hours of ACA treatment will be used for gene and protein assays. This 
is because the IC50 value at 24 hours incubation was higher concentration compared to IC50 at 
48 hours incubation. Thus, the higher concentration will drastically cause cell death which 
could affect and alter the expression and function of genes and proteins.  Therefore, IC50 values 
at 48 hours incubation were the selected concentration for the equally efficacious effect of ACA 











2.3.1.2 Invasion assay 
The inhibitory effect of 1’ acetoxychavicol acetate on cell migration and invasion in 
endocrine-resistant breast cancer cells was investigated by the matrigel invasion assay 
MCF7/LCC2 and MCF7/LCC9 cell lines were cultured on 24-well plate at 37°C in 
humidified air and 5% CO2 for 24 hours. Following this incubation period, the medium was 
removed and replaced with fresh, containing ACA at three non-toxic concentrations. Medium 
with 0.1% EtOH was used as a negative control. Cells were incubated for 48 hours before 
coating the invasion chamber with matrigel and incubating for another 24 hours before 
performing further experiments. After the incubation of matrigel, the cells were harvested using 
Trypsin/EDTA and plated 1 × 105 cells/mL for 150 µL of cells suspension into the upper 
chamber (final cell density 50,000 cells in 150 µL). Then the cells were treated with 7.5 and 
15 µM ACA in MCF7/LCC2 cells and 10 and 20 µM ACA in MCF7/LCC9 cells then incubate 
for 24 hours. 0.1% EtOH was used as a negative control. After the incubation, non-invaded 
cells were scraped off from the upper chamber with a cotton swab and fixed the invasive cells 
with 4% formaldehyde and stained with crystal violet dye. Invasive cells were counted for 25 
random fields under an inverted microscope and analysed the proportion invasiveness. 
 
The proportion invasiveness was calculated from the formula below;  
Proportion invasiveness (%) = number of invaded cells in treated group x 100% 
number of invaded cells in control group 
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2.3.1.3 Gene expression analysis 
 The inhibitory effects of 1’ acetoxychavicol acetate on the expression of genes and 
proteins involved in cell proliferation, migration, invasion, angiogenesis, and tamoxifen 
resistance were studied by quantitative real-time-PCR. 
MCF7/LCC2 and MCF7/LCC9 cell lines (50,000 cell/well) were cultured on a 6-well 
plate at 37°C in humidified air and 5% CO2 for 24 hours. After that medium was removed and 
added 1’ acetoxychavicol acetate at the concentration of IC50, IC25, and IC12.5. Ethanol at 0.1% 
was used as a negative control then incubated for 24 hours. RNA was extracted from the cells 
after complete incubation using Trizol reagent. The cells were rinsed using PBS and lysed with 
1 mL of Trizol reagent and scraped off the adherent cells. Then, the Trizol added cells were 
transferred into 0.2 mL tubes and added 200 µL of chloroform (0.2 mL of chloroform/1 mL 
Trizol) and vortexed the sample vigorously for 15 seconds and incubated 3 minutes at room 
temperature. After that, the samples were centrifuged at 12,000 g, 4 degree Celsius for 15 
minutes. After centrifugation, the samples were separated into lower pink, phenol- chloroform 
phase, an interphase, and a colourless upper aqueous phase. The samples in upper aqueous 
phase were transferred carefully into new 0.2 mL tubes as the RNA remained mainly in the 
aqueous phase. The samples were then going through precipitation steps. The samples were 
mixed with 500 µL of isopropyl alcohol (0.5 mL of isopropyl alcohol/1 mL Trizol) and 
incubated the samples at room temperature for 10 minutes. The samples were centrifuged at 
12,000 g, 4 degree Celsius for 10 minutes. After that, the supernatants were removed, and the 
RNA pellets were washed using 1 mL of 75% ethanol/DEPC-treated water and centrifuged 
7,500 g at 4 degree Celsius for 5 minutes.  
Before performing real-time qPCR, the RNA was measured the concentration via 
spectrophotometry using NanoDrop spectrophotometer. The RNA was air-dried for 10 minutes 
and diluted the RNA with 20 µL of DEPC-treated water then measured absorbance at 260 nm 
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and 280 nm. After that, the RNA was converted to complementary DNA (cDNA) using 
ImProm-II reverse transcription system. 
The real-time qPCR using SYBR green was performed using cDNA as a template with 
primers (Table 2.3.1.3.1) specific for Cyclin D1 (CCND1), NCOA3, MYC proto-oncogene (c-
Myc), CXCR4, uPA, VEGF, and FGF2 under the following conditions: amplification at  95°C 
for 15 seconds, extension at 60°C for 30 seconds and denaturation at 72°C for 30 seconds for 
40 cycles  followed by a melt curve stage (95°C for 15 seconds, 60°C for 1 minutes, 95°C for 
15 seconds), and holding stage (50°C for 2 minutes, 95°C for 2 minutes) for one cycle. 
 
Table 2.3.1.3.1. Primer sets and sequence for studied genes 
Primer set Primer Sequence 
Cyclin D1 Forward 5’-GGATGCTGGAGGTCTGCGAGGAAC-3’ 
 Reverse 5’-GAGAGGAAGCGTGTGAGGCGGTAG-3’ 
CXCR4 Forward 5’-AATGTAGTAAGGCAGCCAACAG-3’ 
 Reverse 5’-CTTCTACCCCAATGACTTGTGG-3’ 
NCOA3 Forward 5’-GGTAGGCGGCATGAGTATGTC-3’ 
 Reverse 5’-TGTTACTGGAACCCCCATACCT-3’ 
VEGF Forward 5'-GAGATGAGCT TCCTACAGCAC-3' 
 Reverse 5'-TCACCGCCTCGGCTTGTCACAT-3' 
FGF2 Forward 5’-GAGAAGAGCGACCCACACG-3’ 
 Reverse 5’-GGCACACACTCCCTTGATAGA-3’ 
uPA Forward 5’-AAATGCTGTGTGCTGCTGAC-3’ 
 Reverse 5’- AGGCCATTCTCTTCCTTGGT-3’ 
c-Myc Forward 5’- AAAGGCCCCCAAGGTAGTTA-3’ 
 Reverse 5’- GCACAAGAGTTCCGTAGCTG-3’ 
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2.3.1.4 Protein expression analysis: Western blotting analysis  
Whole-cell extracts were prepared by lysing the cells with RIPA buffer containing 150 
mM NaCl, 50 mM Tris HCl (pH 8), 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 
protease inhibitor and phosphatase inhibitor cocktails (Sigma- Aldrich). The cell extracts were 
separated by 7.5% SDS-PAGE or 17% 7.5% SDS-PAGE and transferred onto a polyvinylidene 
difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). Samples were incubated in 
blocking buffer [0.1% Tween 20 and 5% nonfat milk powder in Tris-buffered saline (TBS)] 
for 1 h at room temperature. Afterward, the membrane was incubated with primary antibody 
in blocking buffer overnight at 4 °C before being washed twice with TBST (0.1% Tween in 
TBS) and incubated with the appropriate secondary antibody at the concentration of 1:3000 in 
blocking buffer for 1 h at room temperature. The blot was developed using ECL Western 
blotting substrate (Millipore) and analysed using a luminescent image analyzer (C-DiGit Blot 
Scanner, US). The primary antibodies used were the following;  
• rabbit anti-NCOA3 antibody 1:1000 dilution (Cell signaling Technology) 
• rabbit anti-HER2 antibody 1:1000 dilution (Cell signaling Technology) 
•  rabbit anti-ERK 1/2 (phospho-Thr202/Tyr204) antibody 1:1000 dilution 
(Abcam)  
• rabbit Anti-AKT1 (phospho S473) antibody 1:1000 dilution (Abcam)  
• rabbit anti-c-Myc antibody 1:1000 dilution (Cell signaling Technology) 
• mouse anti- uPA antibody 1:1000 dilution (Abcam) 
• mouse anti-FGF2 antibody 1:1000 dilution (Merck Millipore) 
• mouse anti-BCL2 antibody 1:1000 dilution (Cell signaling Technology) 
• rabbit anti-MCL1 antibody 1:1000 dilution (Cell signaling Technology)  
• rabbit anti-PARP antibody 1:1000 dilution (Cell signaling Technology) 
• rabbit anti-cleaved-PARP antibody 1:1000 dilution (Cell signaling Technology) 
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• rabbit anti-p-SAPK/JNK antibody 1:1000 dilution (Cell signaling Technology) 
• rabbit anti-SAPK/JNK antibody 1:1000 dilution (Cell signaling Technology) 
• rabbit anti-GADPH antibody 1:2000 dilution (Sigma-Aldrich) 
• anti-rabbit IgG, HRP-linked antibody 1:2000 dilution (Cell signaling 
Technology) 





2.3.2 In vivo studies 
  2.3.2.1 Acute toxicity test 
The zebrafish embryo toxicity test was performed according to the published 
Organisation for Economic Co-operation and Development (OECD) Test Guidelines (TG236) 
for a Fish Embryo Toxicity (FET) test (237). For each experiment 20 fertilised eggs at the 
beginning of the epiboly stage (0.50 hours) were used. The selected eggs were exposed to 
1,000 µL of 10, 20, 40, 80, and 100 µM ACA in 0.1% EtOH in E3/PTU medium. The samples 
were incubated at 28°C for 24, 48, 72, and 96 hours post fertilisation (hpf) and embryonic 
development was observed with Leica microscope after 24, 48, 72, and 96 hpf. The safety 
concentration from this experiment will be used for further in vivo antiproliferation of ACA. 
The information from this toxicity tests were used as a supportive data for the safety 
concentration for further in vivo experiment. 
 
2.3.2.2 Zebrafish vessel staining 
Dehydration of zebrafish 
The zebrafish embryos were dechorionated and fixed at 72 and 96 hpf with 4% 
Paraformaldehyde (PFA) - store at 4o C overnight. After that fixed embryos were rinsed with 
Phosphate-Buffered Saline/Tween-RNAse (PBST-RNAse) free for 5 mins twice by using a 
shaker. The embryos were then dehydrated with methanol (MeOH) in a 25% increase series. 
The dehydration steps starting with 25% MeOH/75% PBST-RNAase free for 3 minutes, 50% 
MeOH/50% PBST-RNAase free for 3 minutes, 75% MeOH/25% PBST-RNAse free for 3 
minutes, and 100% MeOH for 3 minutes twice. After finish the dehydration process the 
embryos were kept in in 100% MeOH and stored at -20o C for future vessel staining experiment 
as it can last for 3 months. 
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Rehydration of zebrafish 
Before using the dehydrated embryos for performing vessel staining, the embryos were 
required to perform the rehydration by reverse steps of dehydration process. In the rehydration 
process the embryos were performed without the use of shaker. 
Staining (alkaline phosphatase activity), RT 
The embryos were rinsed with alkaline phosphatase (AP) buffer/0.1%Tween for 10 
mins twice. Freshly prepare 5-bromo-4-chloro-3-indolyl phosphate (BCIP)/nitro blue 
tetrazolium (NBT) staining mix (substrate of AP) by using NBT stock solution 1 µL, BCIP 
stock solution 3.5 µL and adjust with AP buffer/0.1%Tween to get 1 ml. Then the embryos 
were moved from 1.5 ml tube into 24 well-plate and removed AP buffer/0.1%Tween. Added 
300 µL of NBT/BCIP staining mix into the embryos and incubated in the dark for 60 minutes 
and observed every 15 minutes under microscope. After 60 minutes of incubation, PBST-
RNAse free was added to stop the staining reaction after that images of the vessels were taken. 
The optimisation of staining time was validated before performing the experiment (additional 
information can be found in Appendix E). The results from this test will be taken into 





 The early-stage embryos (48 hpf) of Danio Rerio (Tubingen AB) were used in in vivo 
observation of growth changes in CM-Dil-labeled MCF7/LCC9 cell transplantation, and were 
immune insufficient to allow the growth of human cells. Before the injection process, zebrafish 
embryos needed to be selected for a particular stage followed by dechorionation. Then the 
embryos were anaesthetised using 0.4% tricaine and mounted on the agar for the nanoinjection. 
ACA was treated into zebrafish medium at 1 day post injection (dpi). The MCF7/LCC9 cell 
growth in zebrafish embryos was observed at 1 day post injection and 3 days post injection 
(238). CM-Dil-labeled  MCF7/LCC9 cells  injected in the yolk of zebrafish could be observed 
by fluorescence microscopy 1 dpi, and retained fluorescent-labeled MCF7/LCC9 cell for 3 
days, providing an sufficient range for ACA screening (239). Quantification of tumour area (n 
= 23/group) was performed using image acquisition (LAS Va.12), quantitative image software.  
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Figure 2.3.2.3.1. The processes of nanoinjection of MCF7/LCC9 labeled CM-dil into the yolk 
sac of zebrafish. The zebrafish embryos at 48 hpf were dechorinated and anaesthetized before 
the injection. The tumour areas of the injected zebrafishes were observed the tumour area 
everyday under fluorescent microscope for 3 days.  
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2.3.3 Molecular docking simulation 
The molecular docking simulation was performed by Dr. Panupong Mahalapbutr. The 
crystal structures of HER2 (PDB ID: 3RCD (240)), AKT1 (PDB ID: 4GV1 (241)), ERK2 (PDB 
ID: 5NHJ (242)), ER (PDB ID: 3ERT (243)), uPA (PDB ID: 5YC7 (244)), CDK6 (PDB ID: 
1XO2 (245)), and FGF2 (PDB ID: 1FQ9 (246)) were obtained from Protein Data Bank. The 
three-dimensional (3D) structure of all the studied ligands were built and fully optimised by 
the HF/6-31(d) level of theory using Gaussian09 program (247). The protein-ligand complexes 
were generated using CDOCKER module implemented in Accelrys Discovery Studio 2.5Accelrys 
Inc. (248) with 100 independent docking runs. Note that the co-crystalised inhibitors were 
defined as docking centre with a spherical radius of 15 Å. 
 
2.3.4 Data and Statistical Analysis 
Results were represented as mean and standard deviation. Data was analysed and 
graphed with GraphPad Prism, version 6.0. The in vivo study, G power programme was used 
for sample size calculation and tumour area and SIV length determination was analysed using 
image acquisition (LAS Va.12), quantitative image software. Significant differences between 
the mean values within the group were determined by using a Student’s t test or one-way 
analysis of variance (ANOVA) followed by a Tukey’s test for further comparison. The level 
of significant was set up at p ≤ 0.05.  
 
2.3.5 Ethical consideration 
The human cell lines used in this study were reviewed and exempted by the Institutional 
Review Board of the Faculty of Medicine, Chulalongkorn University (IRB Number: 616/60). 
The animal ethic for zebrafish study was reviewed by Siriraj Animal Care and Use Committee 
(SiACUC), Faculty of Medicine, Siriraj Hospital (SI-ACUP 006/2559). 
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CHAPTER 3 
STRUCTURAL ELUCIDATION OF ACA 
3.1 Results: Structural elucidation of 1’-acetoxychavicol acetate 
The purity of crude hexane extract was initially checked by spot thin layer 
chromatography which was comparable with the crude working standard of galangal extract 
(Figure 3.1.1). After the initial check with spot TLC, the crude hexane extract was further 
purified  through column chromatography. Subsequently, the chromatographic fractions of the 
compound were evaluated the purity by using 1H-NMR, 13C -NMR, and mass spectroscopy 
and compared the spectra with published purified ACA.   
 
 
Figure 3.1.1. Spot thin layer chromatography of crude hexane extract. The figure showed 




The typical chemical shift values of organic compound in part per million (ppm) 
relative to tetramethylsilane was showed for emphasising proton in functional groups, which 
bolster the interpretation of the chemical shift values of ACA in 1H-NMR spectrum. The 1H-
NMR spectrum was interpreted into four mains information. Firstly, the number of groups of 
signals there were in the spectrum. Secondly, types of proton indicated as the chemical shift of 
each group. Thirdly, the number of protons of each group indicated as an integration which 
was the area under the peaks that proportioned with proton numbers. Finally, the coupling 
patterns which represented proton numbers of adjacent carbon that caused the signals to be 
split into "n+1" lines.  The 1H NMR data (Figure 3.1.2 - 3.1.3, Table 3.1.1) showed 14 
protons in the molecule. Two symmetrical doublets at 7.38 and 7.08 ppm were four protons on 
a para-substituted benzene ring. The proton resonances at 5.99 (1H, m), 5.38 (1H, dd, J = 16.2, 
1.2 Hz), 6.23 (1H, d, J = 6.0 Hz), correspond to protons on 2’ and 3’ – olefinic carbons, 
respectively. The signal at 5.23 (1H, d, J = 10.2, 1.2 Hz) correspond to proton 1’ carbon. Two 
methyl signals of two acetyl groups were clearly due to the presence of two singlet signal at 
2.27 (3H, s), 2.08 (3H, s). 
 
Figure 3.1.2. The typical chemical shift values of organic compounds (parts per million; 
ppm) compared to tetramethylsilane (249). The diagram shows the chemical shift values of 
organic compounds in parts per million (ppm) relative to tetramethylsilane. 
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Figure 3.1.3. 1H-NMR spectrum of ACA 
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The 13C NMR (Figure 3.1.4, Table 3.1.1) displayed the 13C signals. Among these, two 
methyl signals were clear due to the presence of chemical shift value of 20.8 and 20.9 ppm. 
Two carbon signals at 169.1 and 169.6 ppm were typically from carboxyl groups. Two parts 
of carbon signal have chemical shifts at 128.2 and 135.8 ppm, and two quaternary carbon 
signals at 136.2 and 150.4 confirming a para substituted benzene ring. The downfield sp2 
carbons at δc 150.2 (C-1) indicated the presence of oxygen group attached to an aromatic 
carbon. The carbon signal with the chemical shift of 121.5 and 116.8 ppm should be assigned 
as sp2 carbons at 2’ and 3’, respectively. The downfield sp3 carbons at δc 75.3 (1’-C) indicated 
the presence of oxygen that attached to a carbon.   Combination of the fragments mentioned 
above led to assignment of structure of compound ACA. Therefore compound A was identified 
as (1‘S)-1’-acetoxychavichol acetate (250). 
The high-resolution mass spectrum (Figure 3.1.5) showed a molecular ion peak 
[M+Na] at m/z 257.0786 corresponding to a molecular formula of C13H14O4+Na. The 
identification of ACA structure was confirmed by the NMR and mass spectra with published 
articles of Azuma et al. (251). The structure of 1’-acetoxychavicol acetate and its appearance 
were showed in Figure 3.1.6 (additional information can be found in Appendix A).  
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Figure 3.1.4. 13C-NMR spectrum of ACA  
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Table 3.1.1. The 1H and 13C NMR spectra of 1’ acetoxychavichol acetate 
Position                         1’ Acetoxychavichol acetate 
δc, mult.a δH, mult., J in Hz 
1 150.2, s  
2 128.2, d 7.08  d, (8.5) 
3 135.8, d 7.38 d, (8.4) 
4 136.2, s   
5 135.8, d 7.38 d, (8.4) 
6 128.2, d 7.08  d, (8.5) 
1’ 75.3, d 5.23, dd, (10.2, 1.2) 
2’  116.8, d 5.99, m   
3’a 121.5, d 5.38, dd, (16.2, 1.2) 
3’b   6.23, d, (6.0) 
1’-COO  169.1, s             
-CH3 20.9, q 2.08, s           
 1-COO   169.6, s    



















Figure 3.1.5. Mass spectrum of ACA. The figure shows a molecular ion peak [M+Na] at m/z 


















Purified ACA is a natural product that exerts anticancer effects by inducing apoptosis, 
inhibiting angiogenesis and metastasis (172, 174). This study performed multidisciplinary 
processes of crude extraction, purification, and identification. Plant identification was essential 
as the source and period to collect the plant associated with the quality of plant and the number 
of significant compounds as well as the species of this genus was similar to each other (233). 
Also, the parts of the plant (e.g. leaves, pseudostem, roots, rhizomes, and aerial parts) are the 
critical factor as different parts of the plant can be extracted different plant-derived compounds 
in terms of the amount and type of major compounds (233). Besides, appropriate solvents and 
extraction techniques are also crucial for the extraction of different parts of the plant (252). The 
organic solvents that commonly used for plant-derived compounds extraction are methanol, 
ethanol, ethyl acetate, hexane, dichloromethane, aqueous, chloroform, and petroleum ether 
(233).  
In this study, hexane was used as a solvent for cold extraction as it was nonpolar and 
effective for oil extraction. In this step, the rhizomes were chopped and ground using mortar 
into tiny pieces for increasing the surface area of contacting with the solvent to bolster a more 
efficient extraction. The crude hexane extract of ACA was performed spotted on thin layer 
chromatography and compared with crude extract of ACA from Chulabhorn Reseasrch 
Institute, Thailand. Then the crude extract was passed through column chromatography to 
isolate the purified fraction of ACA. The purified ACA was analysed by multidisciplinary 
spectroscopy to identify proton numbers and positions, as well as carbon groups in the 
structure. High-performance mass spectroscopy was performed to investigate the molecular 
weight of the purified ACA. The 1H-NMR and 13C-NMR spectra for ACA from this study were 
identical to the 1H-NMR and 13C-NMR spectra obtained from the working standard of 
Chulabhorn Research Institute, as well as spectra published by Azuma et al and Seo et al (160, 
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250, 251). Also, the high- performance mass spectroscopy spectrum demonstrated the 
molecular weight of purified ACA from this study as identical to the molecular weight of 
published ACA (253).  Therefore, the recorded spectroscopy data confirmed that the pure 
compound was identical to 1’- acetoxychavicol acetate, using one-dimensional 1H-NMR and 
13C-NMR spectroscopy followed by mass spectroscopy, compared to published ACA (250, 
251, 253).   
Identification of the chemical structure is essential as it is associated with the biological 
activity of such compound. Murakami and colleagues reported the SAR of ACA that the 
acetoxyl group at the para position and the  acetoxyl group at 1’ carbon position were 
compulsory for cytotoxic activity (254). This implied that the functional group at 1’ position 
and the phenolic hydroxyl group needed to be acetylated. Also, the double bond at 2’ carbon 
was essential for the activity (254). Different substitution groups of the compulsory groups 
affected the pharmacological activities of the compounds, for example, without the acetoxyl 
group at the para position and the acetoxyl group at 1’ carbon position as well as different 
orientational isomer of phenolic group of ACA can affected cytotoxic activity (254).  
ACA isolated in this study was structural identity with published 1’-acetoxychavicol 
acetate pure compound from the work of Murakami et al and Azuma et al (251, 254). The 
results also showed that ACA structure composed of type and orientation of substitution 
groups, and pharmacophore that was crucial for anticancer, which were acetoxyl group at the 
para position and the acetoxyl group at 1’ carbon position as well as phenolic group at the para 
position. Also, the purity of ACA was more than 97% as shown by the recorded 1H-NMR and 






IN VITRO ACTIVITY OF ACA ON BREAST CANCER CELL LINES 
 
4.1 Results 
4.1.1 Cytotoxic activity of ACA on breast cancer cells 
Prior performing the cytotoxic effect of ACA treatment on breast cancer cells, the effect 
of vehicle control (0.1%EtOH in completed medium) on cell viability compared to untreated 
control (completed medium) was examine in MCF7, MCF7/LCC2, and MCF7/LCC9 cells at 
24, 48, and 72 h (Figure 4.1.1.1). The result demonstrated that the vehicle control was not 
cytotoxic to the cells which can safely be used for dissolving ACA to be used for the further 
studies.  
The percentage viability of MCF7 (Figure 4.1.1.2a), MCF7/LCC2 (Figure 4.1.1.2b), 
and MCF7/LCC9 (Figure 4.1.1.2c) significantly decreased after treated with ACA at 
increasing concentration (0-60 µM) in the concentration- and time- dependent manners (Table 
4.1.1.1). The bright field images of MCF7, MCF7/LCC2, and MCF7/LCC9 after treatment 
with ACA for 48 hour has shown in Figure 4.1.1.3. The studied cell lines were treated for three 
different incubation time which were 24, 48, and 72 hours. There was a significant difference 
of IC50 value in each cell line. The IC50 value of ACA was higher in the endocrine-resistant 
cell lines (MCF7/LCC2 and MCF7/LCC9) than a wide-type breast cancer cell line (MCF7). 
Therefore, the concentration used for further experiments needed to be selected based on the 
concentration acquired from the viability assay. The IC50 value of ACA at 48-hour incubation 
time and its two-fold dilution of each cell line were selected and used for further in vitro 
experiments as the concentrations did not cause major cell death which interfere the 
interpretation of the study results as further in vitro studies were treated ACA for 24 h 
treatment. 
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The positive controls in this study were chosen differently based on the standard 
treatment and sensitivity to the drug of a particular cell line. MCF7 was a tamoxifen sensitive 
cell line, and therefore, 4-hydroxy tamoxifen (4OH-TAM) was used as a positive control.  
MCF7/LCC2 and MCF7/LCC9 were no information reported the sensitivity to drugs; hence, 
the selection of positive control used for these two cell lines was selected using the information 
of known resistant-breast cancer cell lines. MCF7/LCC2 and MCF7/LCC9 had molecular 
characters similar to HER2-overexpressed cell lines such as SKBR3 and AU565 regarding ER, 
PR and HER2 (228, 255, 256). In addition, there was a report stated that the cyclin-dependent 
kinase inhibitor, palbociclib (Pal) was effective for metastatic breast cancer (45, 257-259). 
Therefore, Pal was selected and used as a positive control for MCF7/LCC2 and MCF7/LCC9. 
Tamoxifen resistant test was also performed in MCF7, MCF7/LCC2 and MCF7/LCC9. 
This experiment aimed to confirm that the resistant cell lines had higher IC50 value compared 
to a wild-type MCF7. The result suggested that MCF7/LCC2 and MCF7/LCC9 was resistant 





Figure 4.1.1.1. The effects of vehicle control on viability of untreated controls. The viability 
assay compared the effect of complete medium (untreated control) and 0.1%EtOH in complete 
medium (vehicle control) on MCF7, MCF7/LCC2, and MCF7/LCC9 cells at 24, 48, and 72 h. 
Data are represented as mean ± SEM of three independent experiments (n = 3) and each 
experiment was performed in triplicate. 
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Figure 4.1.1.2. The viability assay of ACA. The percentage viability of MCF7 (a), 
MCF7/LCC2 (b), and MCF7/LCC9 cells (c) after treated with ACA at increasing concentration 
for 24, 48, and 72 h compared with vehicle control. The cell lines were treated with the positive 
controls for 48 h. A positive control used for MCF7 cell was 4-hydroxy tamoxifen (4OH-TAM) 
while palbociclib (Pal) was used for MCF7/LCC2 and MCF7/LCC9 (d). 0.1%EtOH was used 
as a vehicle control for ACA and 4OH-TAM treatment, while 0.2%DMSO was used as a 
vehicle control for Pal treatment. Data are represented as mean ± SEM of three independent 
experiments (n = 3) and each experiment was performed in triplicate, *p≤ 0.05, 0p	 ≤ 0.01, #p 





Figure 4.1.1.3. Bright field images of MCF7, MCF7/LCC2, and MCF7/LCC9 after treatment 
with ACA at increasing concentrations  for 48 h. 
 
Table 4.1.1.1. The comparison of IC50 values of ACA on MCF7, MCF7/LCC2, and 
MCF7/LCC9 cell lines 
Cell lines IC50 (24 h) IC50 (48 h) IC50 (72 h) 
MCF7 19.54 µM ± 1.24 11.78 µM ± 0.50* 5.01 µM ± 0.46*, ** 
MCF7/LCC2 40.44 µM ± 1.84 31.46 µM ± 1.00* 18.62 µM ± 0.69*, ** 
MCF7/LCC9 59.51 µM ± 2.04 41.38 µM ± 1.80* 34.56 µM ± 1.94*, ** 
 
IC50 Values (µM) of ACA obtained by MTT assay after 24, 48, and 72 h of the treatment against 
MCF7, MCF7/LCC2, and MCF7/LCC9 cell lines. Values showed as mean IC50 ± SEM, n = 3, 
*p≤ 0.05 and **p≤ 0.05 compared to each particular cell at 24 and 48 hours of incubation time, 
respectively. 
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Figure 4.1.1.4. The effect of 4OH-Tam in MCF7, MCF7/LCC2, and MCF7/LCC9 cell lines. 
Tamoxifen resistance was determined after treating cells with 4OH-Tam for 120 hours using 
MTT assay (mean ± SEM, n = 3). The medium used for this assay was improved MEM (Gibco, 
USA) supplemented with 2% Charcoal stripped FBS, 1% penicillin streptomycin, and 1% 
insulin. The IC50 values for MCF7, MCF7/LCC2, and MCF7/LCC9 cells were 3.13 µM ± 1.55, 
5.71 µM ± 2.70, and 5.98 µM ± 2.19, respectively. 0.1%EtOH was used as a vehicle control. 
Data are represented as mean ± SEM of three independent experiments (n = 3) and each 
experiment was performed in triplicate, *p < 0.05 compared to control of each cell line and op 







































4.1.2 The in vitro toxicity test of ACA on primary dermal fibroblast cell (PCS201-
010) 
ACA has treated the cytotoxicity with primary dermal fibroblast (PCS201-010) cell for 
48 hours, and the result showed that ACA up to 80 µM did not significantly reduce the viability 
of the PCS201-010 cell (Figure 4.1.2.1). Therefore, the selected concentrations of ACA for 
the further experiments were selected with regard of both in vitro toxicity test from this 




Figure 4.1.2.1. The in vitro toxicity test of ACA on PCS201-010. The percentage viability of 
primary dermal fibroblast (PCS201-010) cells was measured after treatment with ACA at 
increasing concentration for 48 h. The concentration of ACA up to 80 µM caused no significant 
cytotoxicity to PCS201-010. 0.1%EtOH was used as a vehicle control. Data are represented as 
mean ± SEM of three independent experiments (n = 3) and each experiment was performed in 






























4.1.3 Antiproliferative activity of ACA in endocrine-resistant breast cancer cells 
HER2 receptor is a receptor of tyrosine kinase which found to express in breast cancer 
approximately 20 – 30% (33). Current drugs treatment for breast cancer expressed HER2 
receptor are trastuzumab mechanistic work by blocking HER2 receptor and lapatinib wherein 
blocking the tyrosine kinase domain inside the cytoplasm (260). However, the responsiveness 
of breast cancer cell is not preferable (261). This study showed the basal level of the studied 
proteins namely, HER2, NCOA3, AKT, c-Myc, uPA, ERK1/2, and FGF2. The result 
demonstrated the higher protein expression trend in endocrine-resistant cell lines compared to 
a wild-type MCF7 cell line (Figure 4.1.3.1). ACA showed the potential to downregulate HER2 
receptor in all studied cell line. Albeit, ACA seems to have better effects on HER2 
downregulation in tamoxifen-sensitive breast cancer MCF7 cell (Figure 4.1.3.2a) than those 
tamoxifen-resistant breast cancer MCF7/LCC2 (Figure 4.1.3.2b) and tamoxifen-fulvestrant 
resistant breast cancer MCF7/LCC9 cell (Figure 4.1.3.2c). These results can be interpreted 
that ACA has a preferable function on breast cancer resistant cell lines than the tamoxifen-
sensitive breast cancer cells.  It was confirmed by the statistical analysis from the results 
wherein ACA significantly reduced the expression of the HER2 protein level much more 
efficient in MCF7/LCC9 starting at IC25 value. While in MCF7/LCC2 and MCF7, ACA can 





Figure 4.1.3.1. Basal level of studied proteins in MCF7, MCF7/LCC2, and MCF7/LCC9 cell 
lines. The protein bands in western blots and bar charts of densitometry, showed the baseline 
expression levels of 7 studied proteins namely, HER2, NCOA3, AKT, c-Myc, uPA, ERK1/2, 






Figure 4.1.3.2. The effects of ACA on pHER2 and HER2 protein expressions on MCF7,  
MCF7/LCC2 and MCF7/LCC9 cell lines. The bar chart shows the expression level of pHER2 
quantified with GAPDH, pHER quantified with total-HER2, and total form of HER2 quantified 
with GAPDH.  ACA downregulated HER2 protein expression in ER positive tamoxifen 
sensitive MCF7 cell (a) and endocrine-resistant MCF7/LCC2 (b) and MCF7/LCC9 (c) cell 
lines at increasing concentrations after 24 hours of ACA treatment. Data are represented as 
mean ± SEM of three independent experiments (n = 3), *p ≤ 0.05,  **p ≤ 0.01, ***p ≤ 0.001, 
and ****p ≤ 0.0001 compared to vehicle control. 
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 Signalling cascades through PI3K/AKT and ERK1/2 also play an essential role in breast 
cancer progression and these molecules are downstream pivotal molecules of HER2 signalling 
(262). Also, both PI3K/AKT and ERK1/2 were involved in the phosphorylation of NCOA3 
which was important in the proliferation and survival of breast cancer cell (39).  
Hyperactivation and overexpression of ERK1/2 and AKT were found in tamoxifen-resistant 
breast cancer cells (263). Overexpression and activation of growth factor receptors, such as 
EGFR, HER2 and IGF1R, drive the proliferation and survival through activation of MAPK 
and PI3K/AKT signalling pathways in endocrine-resistant breast cancer (37). Overexpression 
of constitutively active AKT in breast cancer cell lines can induce oestrogen independence and 
resistance to tamoxifen and fulvestrant (71), while inhibition of PI3K or AKT restores 
tamoxifen sensitivity (72).  
The results of this study demonstrated that ACA showed less effects on the 
downregulation of pAKT and pERK1/2 on ER positive tamoxifen- sensitive MCF7. As ACA 
can only inhibit the expression of pAKT at the highest concentration (10 µM) used for the 
treatment. Yet, there were no significant differences in the expression of pERK1/2 in ACA-
treated MCF7 compared to control (Figure 4.1.3.3a). While, ACA effect on MCF/LCC2 at the 
concentration of 7.5 – 30 µM has shown the repression of pERK1/2 and pAKT (Figure 
4.1.3.3b). Similarly, ACA at the concentration of 10 – 40 µM has significantly down-regulated 
pERK1/2 and pAKT in MCF7/LCC9 (Figure 4.1.3.3c).  
NCOA3 has been revealed to be overexpressed in breast cancers and pivotally involved 
in oestrogen-mediated cancer cell proliferation (264). In this experiment, NCOA3 mRNA level 
was significantly reduced in ACA-treated MCF7/LCC2 and MCF7/LCC9 cells compared to 
the control. In wild-type ER positive tamoxifen sensitive MCF7 cell, ACA can significantly 
downregulate NCOA3 protein only at the highest concentration (Figure 4.1.3.3a). The 
NCOA3 protein expression was also significantly repressed in ACA-treated endocrine-
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resistant breast cancer MCF7/LCC2 and MCF7/LCC9 cells as a dose-dependent manner 
(Figure 4.1.3.3b-c). The protein results in MCF7/LCC2 and MCF7/LCC9 cell lines were 
correlated with the gene results. This study showed that potentiality of ACA to inhibit the 
expression of NCOA3 was more potent in hormonal-resistant breast cancer cells than 
hormonal-sensitive cell.  
This study highlighted that the effect of ACA on the inhibition of NCOA3 could relate 
with the abolishment of ERK pathway since NCOA3 is phosphorylated by ERK. Consequently, 
the transcription of ER-targeted genes is terminated. More importantly, this work suggested 
that the effects of ACA on breast cancer cells growth functioned through the inhibiting of AKT 
and ERK1/2 signalling pathways which was essential mechanisms of anti-oestrogen resistant 
breast cancer. 
Correlatedly, the protein analysis of ACA treatment showed that ACA potentially 
downregulated c-Myc protein in ACA-treated MCF7 (Figure 4.1.3.3a), ACA-treated 















Figure 4.1.3.3. The effects of ACA on NCOA3, c-Myc, pAKT, and pERK1/2 protein 
expression in MCF7, MCF7/LCC2 and MCF7/LCC9 cell lines and mRNA level of NCOA3 in 
MCF7/LCC2 and MCF7/LCC9 cell lines. The bar chart represents the expression levels of 
pAKT relative to the total AKT protein and pERK1/2 relative with the total ERK1/2 protein. 
NCOA3 and c-Myc protein levels are expressed relative to GAPDH. ACA down-regulated 
pAKT and pERK1/2, NCOA3, and c-Myc protein expression in MCF7 (a), MCF7/LCC2 (b) 
and MCF7/LCC9 (c) cell lines at increasing concentrations after treatment for 24 h. NCOA3 
mRNA expression (relative to GAPDH expression) in MCF7/LCC2 and MCF7/LCC9 cell 
lines (d) was also significantly downregulated in ACA-treated groups compared to vehicle 
control.  Data are represented as mean ± SEM of three independent experiments (n = 3), *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001 compared to vehicle control. 
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4.1.4 Inhibitory effects of ACA on the expression of NFкB targeted genes involved 
in cells migration/invasion and angiogenesis in endocrine-resistant breast cancer cells 
NFкB plays a significant role in cancer progression , and especially it is a key associated 
between inflammation and cancer (265). There was also crosstalk between NFкB and ER 
signalling in endocrine-resistant breast cancer cells (189). The phosphorylation of IKKα  can 
cause by the activation of PI3K signalling, resulting in both ER and NCOA3 increased its 
transcriptional activity and ultimately increased cell cycle progression (189).  
In both ACA-treated MCF7/LCC2 and MCF7/LCC9 cells showed the repression of the 
expression of NFκB targeted genes including, genes that responsible for cell proliferation; 
CCND1 and c-myc in all three concentration (IC12.5, IC25, and IC50) used in the experiment 
(Figure 4.1.4.1a - c). For invasive factors; CXCR4 and uPA, ACA showed that it was more 
effective in MCF7/LCC2 than MCF7/LCC9 cell lines as the concentration than significantly 
downregulated CXCR4 and uPA was seen at the IC25 value (Figure 4.1.4.1c - d). Regarding 
angiogenic factors, ACA can repress the expression of VEGF at the IC50 value. On the other 
hand, the expression of FGF2 was downregulated by ACA treatment at all three concentration 
in MCF7/LCC2 and at IC25, and IC50 in MCF7/LCC9 (Figure 4.1.4.1e - f). Additionally, ACA 
can significantly downregulate uPA and FGF2 proteins in MCF7 cell line at the IC50 (Figure 
4.1.4.2a). While, ACA can repress the expression of uPA and FGF2 proteins in MCF7/LCC2 
and MCF7/LCC9 cells at the concentration of IC25 and IC50 (Figure 4.1.4.2b - c). 
This study revealed that ACA can inhibit the expression of genes involved in survival, 
metastasis/invasion, and angiogenesis of endocrine-resistant breast cancer cells through the 




Figure 4.1.4.1. The inhibitory effects of ACA on down-regulation of CCND1, C-myc, CXCR4, 
uPA, VEGF, and FGF2 mRNA expressions in MCF7/LCC2 and MCF7/LCC9 cell lines. The 
bar chart represents the expression of mRNA levels of studied genes quantified with GAPDH. 
ACA can significantly down-regulated CCND1 (a), C-myc (b), CXCR4 (c), uPA (d), VEGF 
(e), and FGF2 (f) mRNA expressions (as measured using real-time qPCR) on MCF7/LCC2 
and MCF7/LCC9 cell lines at increasing concentrations after the treatment for 24 hours. Data 
are represented as mean ± SEM of three independent experiments (n = 3), **p ≤ 0.01, ***p ≤ 








Figure 4.1.4.2. The effects of ACA on uPA and FGF2 protein expressions in MCF7, 
MCF7/LCC2 and MCF7/LCC9 cell lines. The bar chart represents the expression of uPA and 
FGF2 protein levels quantified with GAPDH. ACA downregulated the expression of uPA and 
FGF2 in MCF7 (a), MCF7/LCC2 (b), and MCF7/LCC9 (c) cell lines at increasing 
concentrations after the treatment for 24 hours with ACA treatment. Data are represented as 
mean ± SEM of three independent experiments (n = 3), *p ≤ 0.05, **p ≤ 0.01, and ****p ≤ 
0.0001 compared to vehicle control.  
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 4.1.5 Anti-invasive activity of ACA on endocrine-resistant breast cancer cells 
The functional assay of ACA on cell invasion was performed using a matrigel invasion 
assay. The selected cell lines for this essay were MCF7/LCC2 and MCF7/LCC9 as these two 
cell lines were more aggressive invasion than the wild-type MCF7 cell (255).   
This study suggested that ACA significantly inhibited cell invasion in endocrine-
resistant breast cancer (Figure 4.1.5.1a - b) at non-toxic concentration. This pharmacological 
invasion assay showed that ACA inhibited invasion of MCF7/LCC2 at 7.5 µM and 15 µM, and 
in MCF7/LCC9 cell line ACA inhibited cell invasion at 10 µM and 20 µM.   This implying 
that ACA can be a promised substance for inhibition of the cancer cell invasion in aggressive 
types of breast cancer.  
However, in vivo study of ACA on antimetastasis and angiogenesis are still required to 
support ACA as an adjuvant treatment for breast cancer resistant to endocrine treatment in 




Figure 4.1.5.1. The anti-invasive activity of ACA in MCF7/LCC2 and MCF7/LCC9 cell lines. 
The invasion assay showed that the relative of cell invasion (%) of MCF7/LCC2 and 
MCF7/LCC9 (a, b) cell lines treated with non-toxic concentration of ACA for 24 hours was 
significantly lower than the control. 0.1%EtOH was used as a vehicle control. Data are 
represented as mean ± SEM of three independent experiments (n = 3), **p ≤ 0.01 and ***p ≤ 
0.001 compared to vehicle control. 
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4.1.6 Shift towards induction of apoptosis 
 The loss of expression and activation of stress-activated kinases (SAPKs) or c-Jun N-
terminal kinases (JNKs) was reported to be involved in various cancers including breast cancer 
(266). To investigate the induction of apoptosis, protein expression of SAPK/JNK and anti-
apoptosis proteins were studied. The three studied cell lines were treated with various 
concentrations of ACA for 24 hours. Interestingly, while ACA-treated MCF7 showed no 
significant changes in the expression of neither phospho-SAPK/JNK nor SAPK/JNK compared 
to non-treated MCF7, ACA treatment of MCF7/LCC2 and MCF7/LCC9 cell lines resulted in 
upregulation of phospho-SAPK/JNK and SAPK/JNK expression up to tenfold compared to the 
control. To further evaluate the induction of apoptosis, the expression of Mcl-1 and Bcl-2 were 
also analysed. ACA exert the ability to downregulate the anti-apoptotic protein Mcl-1 and Bcl-
2 in all three studied cell lines. In addition, ACA exerted the apoptotic induction activity via 





Figure 4.1.6.1. The effects of ACA on apoptotic induction. The bar chart represents the 
expression of SAPK/JNK, cleaved PARP, Mcl-1, and Bcl-2 protein levels quantified with 
GAPDH. ACA induced phospho-SAPK/JNK and cleaved PARP protein expression in MCF7, 
MCF7/LCC2, and MCF7/LCC9 cell lines, while Mcl-1 and Bcl-2 were downregulated in all 
studied cell lines. The studied cell lines were treated with ACA at increasing concentrations 
for 24 hours. 0.1%EtOH was used as a vehicle control. Data are represented as mean ± SEM 
of three independent experiments (n = 3), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 




In the viability study, ACA exerted the growth inhibition of MCF7, MCF7/LCC2, and 
MCF7/LCC9 cell lines in 3-time points (24, 48, 72 hours) at increasing concentrations and the 
IC50 values of each particular time point was calculated. From the comparison of IC50 value of 
each incubation time, ACA showed cytotoxic activity as a dose dependent manner. Besides, 
when compare the IC50 value of all three cell lines at 3-time points. The result showed that 
there was a significant difference between the IC50 value of each time point of the same cell 
line. To be more precise, at 24, 48, and 72 hours of ACA treatment, IC50 value of MCF7, 
MCF7/LCC2, and MCF7/LCC9 cell lines were significantly different. This implied that ACA 
exhibited cytotoxic activity as a time-dependent manner. Also, the results showed that ACA 
had different potency for each cell line. In the in vitro viability test, there were two positive 
controls have been used for the study. 4OH-Tam was used as a positive control for MCF7 cell 
while palbociclib was used for MCF7/LCC2 and MCF7/LCC9.  MCF7/LCC2 and 
MCF7/LCC9 cell lines were resistant to hormonal treatment in which palbociclib was 
recommended for clinically used as combination with endocrine therapy in ER positive 
advanced breast cancers (236).  The cells were also treated with its particular positive control 
for 48 hours at the concentration up to 20 µM. The result showed that in MCF7 cell, 4OH-Tam 
significantly inhibited the growth of MCF7 cell at the concentration of 20 µM which was very 
high concentration. The resistant test of 4OH-tam was performed using MTT assay, and the 
result showed that MCF7/LCC2 and MCF7/LCC9 had the IC50 value two times higher than the 
wild-type MCF7. In this resistant test, the incubation time used for 4OH-tam was 120 hours. 
Tamoxifen generally has cytostatic action rather than cytotoxic action (267). Tamoxifen was 
reported to competitively bind to ER and block the molecular signalling of ER that drives the 
transcriptional activity of ER-regulated genes, thereby promoting breast cancer cell survival 
(268). Therefore, the appropriate incubation time for cytostatic action of tamoxifen was longer 
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than that for the chemotherapeutic agents that possessed cytotoxic activity to cancer cells which 
showed pharmacological activity within 24 hours. Palbociclib-treatment of MCF7/LCC2 and 
MCF7/LCC9, for 48 hours showed that the IC50 values were greater than 20 µM. These results 
imply that the endocrine-resistant MCF7/LCC2 and MCF7/LCC9 cells were possibly resistant 
to the CDK4/6 inhibitor palbociclib. This resistance of MCF7/LCC2 and MCF7/LCC9 cells to 
palbociclib treatment could be explained that these ER-positive cells showed higher baseline 
level of expression of various molecules involved in survival pathways such as HER, NCOA3, 
AKT, ERK1/2, and c-Myc. Therefore, treatment with CDK4/6 inhibitor palbociclib alone may 
not provide effective cytotoxicity to the cells. Additionally, recent evidence has identified that 
ER positive breast cancers could develop resistance to CDK4/6 inhibitors when used in a long-
term treatment,  as an adaptive response via the mutation of Rb protein, which in turn alters the 
growth signalling pathway of CDK4/6, as well as the activation of AKT pathway (236). Also, 
the long-term treatment with CDK4/6 inhibitors can promote acquired resistant of ER positive 
breast cancer to CDK4/6 inhibitors (236, 269).  
In this thesis, the tamoxifen sensitivity test was performed in MCF7, MCF7/LCC2, and 
MCF7/LCC9 cells. The results showed that the ER-positive MCF7/LCC2 and MCF7/LCC9 
cells had approximately two times higher IC50 values compared to a parent MCF7 cell. This 
result indicated that ER-positive MCF7/LCC2 and MCF7/LCC9 cells were tolerant to 
tamoxifen treatment. Also, this study confirmed the phenotypes of the all 3 studied cell lines 
by demonstrating the baseline levels of the proteins (HER2, NCOA3, AKT, ERK1/2, c-Myc, 
uPA, and FGF2) that are involved in the proliferative-, invasive-, and angiogenic-phenotypes 
of the resistant cells, compared to the control parental MCF7 cell. 
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Chemotherapeutic agents used for cancer therapy commonly cause adverse drug 
reactions to normal cells; for example, doxorubicin-induced cutaneous cytotoxicity (270). 
Common  adverse drug reactions associated with cancer chemotherapy include prolonged QT 
interval, papulopustular rash, nail disorders and a hand-foot skin reactions (271). In addition, 
off-target skin reactions have been indicated for several chemotherapeutic drug classes (e.g. 
alkylating agents, antimetabolites, and antitumor antibiotics) with a broad range of cutaneous 
manifestations (272-276). Other common cutaneous adverse effects include anagen effluvium, 
xerosis, thrombophlebitis, generalised pruritus, melanonychia, hand-foot syndrome, and 
extravasation reactions etc (276, 277). Therefore, the primary dermal fibroblast (PCS201-010) 
cell line was selected as a model of normal skin cells for the in vitro toxicity test of ACA. The 
in vitro toxicity test of ACA was tested using PCS201-010 cell and the result after ACA 
treatment for 48 hours showed that ACA up to 80 µM was not toxic to the normal cell. 
Additionally, ACA at 160 µM had approximately 40% cytotoxicity to PCS201-010. This result 
was to emphasise that ACA was not cytotoxic to the normal connective tissues, which was 
important in terms of the application of ACA as a future promised adjuvant therapy in the 
clinic. The toxicity test of ACA on MCF10A cells, a breast epithelial cell line could have been 
used as an additional control cell line to confirm the safety of ACA on a nontumourigenic 
breast cells. MCF10A human mammary epithelial cell is commonly used for studying normal 
breast cancer function and transformation (278). The phenotype of MCF10A in 3D culture was 
positive for basal markers and the milk proteins β-casein and α-lactalbumin, which rarely found 
in normal human breast tissue (278). Therefore, the suitability of using MCF10A as a model 
for studying normal breast cancer is still questioned (278). Also, culturing MCF10A requires 
100 ng/ml cholera toxin to stimulate cell growth (279) , and this toxin is prohibited from 
entering Thailand. These issues hampered the use of MCF10A as a toxicity control cell line. 
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Resistance of breast cancer can be develop either in the beginning of the endocrine 
therapy (intrinsic resistance) and/or during the treatment (acquired resistance) (280). There are 
several molecular mechanisms of ER-positive breast cancer to develop resistant to endocrine 
therapy such as the genetic variation of  cytochrome P450 isozymes, the upregulation of ER 
coactivator (e.g. NCOA3), upregulation of cyclins (e.g. cyclin D and E), the overexpression 
and hyperactivation of PI3K/AKT and ERK1/2, and the activation of NFκB (39, 263, 281). 
Several studies have revealed that the growth factors and its signallings play pivotal roles in 
breast cancer resistance (282). The upregulation of HER2 or EGFR was confirmed to affect 
the expression of ERα in the cell line-based study, and this occurred clinically relevant with 
the responsiveness of ER-positive breast cancer for endocrine treatment (283, 284). Also, the 
high expression of NCOA3 was found to contribute to the agonistic action of tamoxifen to ER 
(285). Therefore, triggering the classical and non-classical genomic pathways of ER signallings 
therein lied tamoxifen resistance of ER-positive breast cancer (285).  One of the important 
survival pathways was the PI3K/AKT pathway, the downstream PI3K can be driven by MEK, 
ERK, and/or JNK (68). This pathway can regulate genes which involved in cell survival and 
notably crosstalk with ERα activation and signalling (68). Cyclin D1 was reported to promote 
the resistance of breast cancer via promoting the high proliferation of cancer cell; moreover, 
amplification of cyclin D1 caused a three-fold higher risk of death in ER-positive breast cancer 
patient (286).  This study has determined the basal level of significant proteins in which related 
to endocrine-resistant breast cancer. It was confirmed that the resistant cell lines used for the 
study which were tamoxifen-resistant MCF7/LCC2 cell and tamoxifen/fulvestrant-resistant 
MCF7/LCC9 expressed higher basal level expression of HER2, NCOA3, AKT, c-Myc, uPA, 
ERK1/2, and FGF2 proteins compared to the wild-type ER-positive tamoxifen-sensitive MCF7 
cell line. MCF7 cell line was characterised molecular subtypes as a luminal A subtype (287). 
However, there was controversy on the expression HER2, which either HER2 negative or very 
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low-grade expression of HER2 (287-289). In addition, this study suggested that ACA could 
have a potential to inhibit key signallings, which involved in the resistant cell lines. 
ACA has been reported to inhibit cell growth and angiogenesis on various cancer cells. 
Albeit, the antiproliferative, anti-invasive, and anti-angiogenic effects through HER2 
signalling, ER coactivator; NCOA3, and NFκB targeted molecules on hormonal-resistant 
breast cancer cells have never been reported. The expression of HER2, a significant growth 
factor receptor for breast cancer in the non-classical genomic pathway, was also determined in 
this study. This protein analysis on total-HER2 expression after 24 hours of ACA treatment 
demonstrated that at the concentration below IC50, ACA could not significantly downregulate 
HER2 expression in MCF7, MCF7/LCC2 cell lines while ACA significantly affected the 
expression of HER2 in MCF7/LCC9 at the IC25 and IC50. In this study, the pHER was also 
performed. In MCF7 cell line, ACA only at the IC50 concentration could downregulate the 
protein expression of pHER2 (normalised with GADPH). While the expression of pHER2 
(normalised with GADPH) in MCF7/LCC2 and MCF7/LCC9 was significantly decreased in 
all three studied concentrations. However, the result of pHER2 protein expression in all three 
cell lines when normalised with total-HER2 did not statistically difference compared to 
untreated control. These results can be implied that the downregulation of pHER2 in ACA-
treated groups was due to the influence of total-HER2 downregulation. Hence, ACA effect on 
HER2 receptor was through the downregulation of HER2 receptor not the activity. 
Among three cell lines, the results noticed that ACA had preferable effects on 
MCF7/LCC9 more than the others. Apart from that, the study of ACA on the expression of 
pERK1/2 and pAKT was also performed. As the pERK1/2 and pAKT were the downstream 
molecules of HER2 signalling (262). Therefore, the insight study for these proteins was 
essential to identify the mechanism of action of ACA on HER2 signalling pathway (262).   The 
results in this study identified that ACA inhibited proliferation through the downregulation of 
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pERK1/2 and pAKT. These finding is consistent with the study of Murakami et al, 2005 that 
ACA showed the potential to inhibit the expression of  pERK1/2 and pAKT which performed 
in RAW264.7 murine macrophages (173). Signalling cascades through ERK1/2 and PI3K/AKT 
are an essential pathway in breast cancer progression (263). Hyperactivation and 
overexpression of ERK1/2 and AKT were found in tamoxifen-resistant breast cancer cells 
(263). 
The antiproliferative effects of ACA was also performed via evaluation of gene and 
protein level by using real-time qPCR and western blotting analysis. The results indicated that 
ACA affected the expression of NCOA3 in both gene and protein levels. The expression of 
NCOA3 protein in endocrine-resistant breast cancer cell lines was higher than ER-positive 
wild-type breast cancer cell. NCOA3 has has been revealed to be overexpressed in breast 
cancers and pivotally involved in oestrogen-mediated cancer cell proliferation (264). In breast 
cancer patients, the expression of NCOA3 was determined, and it showed that NCOA3 
expression was detected in 60 % of the tumours (57). Also, the analysis of clinical samples 
indicated that patients with elevated NCOA3 did not respond well with tamoxifen therein lied 
breast cancer resistance to hormonal therapy (57).  
This study suggested that the treatment with ACA at three different concentrations 
(IC12.5, IC25, and IC50) on MCF7/LCC2 and MCF7/LCC9 caused the repression of NCOA3 
both gene and protein as a dose-dependent manner as can be seen by the significance of all 
concentrations used for the treatment in both cell lines represented in gene and protein results. 
Whereas, in MCF7 ACA can significantly suppress the expression of NCOA3 only at the IC50 
concentration. Intriguingly, ACA exhibited a better efficiency on endocrine-resistant breast 
cancer cells than the ER-positive wild-type breast cancer cell. This study revealed that ACA 
could have a mode of action via the down-regulation of NCOA3 in endocrine-resistant breast 
cancer cells. Hence, ACA could inhibit the transcriptional activity of ER-mediated genes in 
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both classical and non-classical genomic pathways as NCOA3 was a major co-activator of ER 
signalling pathways.   
ACA has been reported to rapidly decrease the nuclear expression of NFκB , but 
increase the accumulation of cytosol NFкB in RPMI82 cells (37). This indicating that ACA 
blocks the translocation of NFкB from the cytosol to the nucleus (168). NFκB plays a 
significant role in cancer initiation and progression (265). ACA has also been reported to 
inhibit angiogenesis in human prostate cancer through VEGF (174). It can inhibit metastasis 
through matrix metalloprotease-9 (MMP-9) (171), whereas the effects of ACA on VEGF and 
FGF2 in endocrine-resistant breast cancer cells have never been reported. NFкB activation was 
originally associated with the progression of hormone-independent breast cancers (107). NFкB 
bestowed transcriptionally to induce genes mediating cell proliferation, such as cyclin D1 
(CCND1) (290-292), c-myc (293) as well as genes that responsible for invasion including 
urokinase-type plasminogen activator (uPA) (294-296) and Chemokine receptor (CXCR4) 
(148, 297, 298) and angiogenic factors such as vascular endothelial growth factor (VEGF) 
(299) and basic fibroblast endothelial growth factor (FGF2) (300-304).  
In this study, we showed that ACA had the potentiality to inhibit the expression of 
NFκB regulated genes that involved in resistant breast cancer cells. NFκB was activated in the 
presence of AKT and ERK1/2 (305-307). The aforementioned effects of ACA on pAKT and 
pERK1/2 could affect the transcriptional activity of NFκB resulting in anticancer activities of 
ACA. Therefore, the downregulation of NFκB regulated genes could be observe in this study. 
More interestingly, with regard to angiogenesis aspect, we pointed out that ACA inhibited not 
only VEGF but also FGF2, which was a critical angiogenic factor in breast cancer. Giavazzi et 
al have revealed that FGF can function synergistically with VEGF to magnify tumour 
angiogenesis (308). This study highlighted that ACA targeted both the FGF and VEGF may be 
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more efficacious in repressing tumour growth and angiogenesis than targeting either factor 
alone. 
Apart from that, ACA shifted up of the pro-apoptotic signal via the upregulation of 
SAPK/JNK protein expression but not the activity. Its effect predominantly affected hormonal 
resistant breast cancer cells rather than the wild-type breast cancer. Evading apoptosis and 
overexpression of anti-apoptotic proteins were found to be the cause of cancer resistance to 
cancer chemotherapeutics and poor prognosis (309-311). Therefore, we also demonstrated the 
apoptotic induction activity of ACA was through the anti-apoptotic factors Mcl-1 and Bcl-2. 
Liew et al showed that ACA induced apoptosis via the induction of the mitochondrial pathway 
(192). Their results supported our study that ACA may have apoptotic induction on hormonal 
resistant breast cancer cells through mitochondrial pathway. 
In conclusion, ACA exhibited anticancer activities through HER2/MAPK/ERK1/2, 
PI3K/AKT pathways as well as through the inhibition of NCOA3. It can also inhibit the gene 
expressions, which involved in proliferation and invasion. As of anti-angiogenic activity, 
ACA potentially repressed both angiogenic factors; VEGF and FGF2.  According to apoptotic 
induction, ACA promoted the expression of pro-apoptotic molecules and repressed of pro-
survival molecules.  
Future studies could investigate the effects of ACA on reversal of tamoxifen sensitivity 
in endocrine-resistance breast cancer cells, compared to endocrine-sensitive breast cancer cells. 
Viability tests, such as MTT or BrDU assays in endocrine-sensitive breast cancer cells could 
be used to compare the IC50 values of ACA-tamoxifen co-treatment with tamoxifen treatment 
alone. Also, performing anti-proliferative assays, such as colony forming assays or anchorage-
independent growth (soft agar assays) plus additional of gene expression and protein 
expression analysis of combined ACA-tamoxifen treatment could be compared to tamoxifen 
treatment alone. This will then give information of the effects of ACA on reversal of tamoxifen 
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sensitivity in endocrine-resistance breast cancer cells. To further explore the effects of ACA on 
HER2 expression, it would be interesting to study the effects of ACA on HER2 over-expressing 
cells (e.g. SKBR3, AU565, HCC1008) as endocrine-resistant breast cancer cells showed 
upregulated of baseline HER2 protein expression. Additionally, the phenotype of endocrine-
resistant breast cancer cells (MCF7/LCC2 and MCF7/LCC9 cells) in this study demonstrated 
the upregulation of molecules such as AKT and ERK1/2 that are downstream of HER2, as well 
as downregulation of ER protein levels. This could support the rationale for further studies of 
ACA in HER2 over-expressing subtypes. In addition to the effects of ACA, which targets 
multiple molecules, the effects of ACA in triple-negative breast cancer cells (e.g. MDA 
MB231, MDA MB436, HCC70) could be interesting experiments. There are several subtypes 
of triple-negative breast cancer patients which are reported to have abnormal gene expression 
profiles. For example, genes for cell-cycle regulation and DNA repair genes (e.g. MYC, 
PIK3CA, CDK6, AKT2, FGFR1) are observed as well as hyperactivation of signalling 
pathways such as EGFR (312, 313). In addition, ACA has been reported in multiple studies to 
have effective anticancer effects on MDAMB231 via apoptosis induction (170, 192). Other 
experiments that will further knowledge of the pharmacological effects of ACA would include 
different culture methods, such as 3D in vitro culture models (e.g. spheroid and organoid 3D 
culture) that could used to determine its effects within the cell microenvironment. Such 





IN VIVO ACTIVITY OF ACA ON ZEBRAFISH MODEL 
 
5.1 Results 
5.1.1 Acute toxicity test of zebrafish embryos 
The acute toxicity test of ACA on zebrafish embryos was done as followed the OECD 
test guideline (TG236). After treated the zebrafish embryos with ACA at increasing 
concentration (up to 160 µM). The result showed that ACA up to 20 µM did not cause any of 
four apical indicators (coagulation of fertilised eggs, lack of somite formation, lack of 
detachment of the tailed-bud from yolk sac, and lack of heart-beat; additional information of 
four apical indicators can be found in Appendix C) to the zebrafish embryos. 
The nondetectable heartbeat, tail-bud detachment, and coagulation of zebrafish 
embryos was initially seen at 48 hours post fertilisation (hpf) of 40 µM ACA treatment. The 
50% lethality concentration (LC50) of ACA at 24, 48, 72, and 96 hpf was shown in Table 
5.1.1.1. and Figure 5.1.1.1.  
This study also illustrated that the LD50 of ACA on zebrafish embryos (at 24, 48, 72, 
and 96 hours), which indicated that LD50 of ACA between 24 and 48 hours (41.20 µM ± 5.03 
and 40.47 µM ± 2.87) and 72 and 96 hours (35.45 µM ± 2.20 and 32.16 µM ± 1.54) did not 




Table 5.1.1.1. The LC50 of ACA on zebrafish embryos at 24, 48, 72, and 96 hpf 
 
Time (hpf) Mean LC50 ± SEM 
24 41.20 µM ± 5.03 
48 40.47 µM ± 2.87 
72 35.45 µM ± 2.20 






Figure 5.1.1.1. The toxicity of ACA in zebrafish embryo was followed OECD guidelines. Top 
figures show images of zebrafish embryos at 48 hpf after ACA treatment. Bottom figure shows 
the 50% lethality concentration (LC50) of ACA at 24, 48, 72, and 96 hpf was 41.20 µM ± 5.03, 
40.47 ± 2.87 µM, 35.45 µM ± 2.20, and 32.16 µM ± 1.54 respectively. 0.1%EtOH in E3-PTU 
was used as a vehicle control. Data are represented as mean ± SEM of three independent 
experiments (n = 3), *P≤0.05 vs. untreated cells (mean ± SEM, n = 3) 
  
























5.1.2 Zebrafish vessel staining  
In this experiment, ACA was treated to zebrafish embryos at 24 hpf for 48 hours. Then 
the whole-mount alkaline phosphatase vessel staining was performed. After staining the vessels 
with alkaline phosphatase, the vessels were easily visualised by using a digital camera and 
image acquisition (LAS Va.12), publicly available quantitative image software. The results 
showed that after 48 hours of ACA treatment, the concentration up to 40 µM did not cause the 
abnormal formation of the subintestinal vessels (SIV) to zebrafish embryos compared to ACA-




Figure 5.1.2.1. The whole-mount alkaline phosphatase vessel staining. ACA (0-40 µM) did 
not inhibit normal SIVs development form on the dorsolateral surface of the yolk on both sides 
of the embryo, as detected using whole-mount alkaline phosphatase vessel staining. Red arrow 
points indicate the SIVs of the zebrafish that lined behind the yolk of the zebrafish. E3-PTU 




5.1.3 Tumour engulfment and proliferation 
The optimisation of conditions for MCF7/LCC9-grafted zebrafish was performed to 
optimise three optimal conditions of tumour-grafted zebrafish survival.   Firstly, the appropriate 
number of cancer cells to be injected without causing zebrafish death (314). Secondly, the 
incubated condition of tumour-engrafted zebrafish (315). Finally, the percentage of tumour 
engulfment (314). 
The result showed that the amount of appropriate cancer cells was 200 cells/5nL. And 
the optimal conditions for tumour-engrafted zebrafish was 36o Celsius, 5%CO2 with 
humidified air. This condition allowed humanised-cancer cell growth without causing 
zebrafish death. Also, this condition did not cause the aberrant staging development of the 
zebrafish 
Regarding the optimal conditions, the cancer cell can efficiently engraft and proliferate 
in the zebrafish as shown by the increase of tumour area and fluorescence intensity at 3 days 
post injection (dpi), which was 1 - 2 times greater than 0 dpi (Figure 5.1.3.1). 
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Figure 5.1.3.1.  Tumour engulfment and proliferation. The injection of endocrine-resistant 
breast cancer cell (MCF7/LCC9) into the yolk sac of zebrafish embryos at 48 hpf (0 dpi). The 
observation of tumour area and fluorescence intensity were measured at 0, 1, 2, and 3 dpi. The 
fluorescence intensity data were represented as relative values quantified with fluorescence 
intensity 0 dpi. A1 - A7 represented zebrafish sample number. 
 106 
5.1.4 The inhibitory effect of ACA on MCF7/LCC9 cells proliferation engrafted 
zebrafish embryos 
Zebrafish has many homolog genes that plays role in crucial signalling pathways 
involved in cell proliferation, apoptosis, metastasis, angiogenesis of human cancers (316, 317). 
With this zebrafish xenograft model is the platform for xenotransplantation approach to 
investigate real-time visualisation of tumour mass (318). 
In this experiment, the zebrafish was injected with MCF7/LCC9 cell for 200 cells/5nL 
at 48 hpf (0 dpi). ACA was treated into the zebrafish medium at 1 dpi. The tumour area was 
regularly observed at 1 and 3 dpi. The result demonstrated that at 3 dpi (48 hours of ACA 
treatment), ACA significantly reduced the tumour area in all studied concentrations in the 
experiments (5, 10, 15 µM). The reduction of tumour area in ACA-treated group was 
approximately four times lesser than the control group (Figure 5.1.4.1). 
This experiment confirmed that ACA exhibited the antiproliferative effect in zebrafish 

































Figure 5.1.4.1.  The antiproliferative effect of ACA in zebrafish model. ACA significantly 
inhibited the tumour area of MCF7/LCC9 cells engrafted zebrafish embryos at 1 and 3 dpi. 
0.1%EtOH in E3-PTU was used as a vehicle control. Data are represented as mean ± SEM of 
three independent experiments (n = 3), ***P≤0.001 and ****P≤0.0001 vs. control at 3 dpi, 
oP≤0.05 vs. the same concentration of ACA treatment at 1 dpi (mean ± SEM, n = 23/group). 
 108 
5.2 Discussion 
Regrading in vivo study of zebrafish, the husbandry and well-being of zebrafish need 
to be considered because different stages of zebrafish had different living conditions (e.g. types 
of food, sizes of food, and water level for their survival) (319).  
The acute toxicity test showed that ACA concentration used for further in vivo 
experiment was not toxic to the zebrafish. Furthermore, the additional toxicity test, alkaline 
phosphatase staining, showed that ACA up to 40 µM did not significantly inhibit normal 
subintestinal vessels (SIVs) development form on the dorsolateral surface of the yolk on both 
sides of the embryo. Both toxicity assays confirmed that the concentration and treatment time 
of ACA used in zebrafish experiment did not toxic to zebrafish, regardless of neither causing 
acute toxicity to zebrafish embryos nor the development of normal SIVs formation. Thus, these 
experiments ascertained that the concentration of ACA did not interfere with the results from 
further in vivo studies.   
Zebrafish (Danio rerio) required regular care and appropriate protocol for staging 
growth (315). Unlike human-derived cancer cells that required human body temperature (37.4 
degree Celsius) to proliferate, but the optimum temperature for zebrafish is 28.5 degree Celsius 
(315).  In the in vivo MCF7/LCC9-implanted zebrafish experiment, the method was never 
published before. Therefore, the transplantation of endocrine-resistant breast cancer cells into 
zebrafish xenograft was needed to evaluate the engraftment efficiency and the optimal 
condition for both human cell and zebrafish was required to be evaluated. Also, in this study, 
some mandatory equipment was needed to be manually modified; for instance, the diameter of 
the microneedle, injection pressure, and injection time. All those conditions affected the 
number of injected cancer cells. The microneedle, in particular, was necessary to be nipped for 
adjusting the inner diametre before performing the nano-injection for a specific cell line. This 
procedure was done to prevent either cancer cell clogged within the microneedle or the 
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uncontrolled number of cancer cell per injection. Regarding, the injection equipment, it was 
set the pressure and time for injection as the same condition in every experiment. However, the 
weight and duration of pushing the paddle for injection could be another significant factor for 
a variation in the cancer cell numbers. Therefore, it could be a variation in the number of cancer 
cells from each experiment. Consequently, the optimisation of conditions for MCF7/LCC9-
grafted zebrafish need to be validated. Also, the number of cancer cells are significant for 
engrafted and proliferative capabilities and zebrafish survival (314). Thus, the tumour 
engraftment and proliferation in zebrafish validation necessitate being done before. Efficient 
engraftment can also be obtained by transplanting cells into early embryo zebrafish that have 
not yet developed a functional acquired immune system.  
By labelling MCF7/LCC9 with a red fluorescent CM-dil dye, this allowed the cells to 
be tracked tumour area and fluorescence intensity.  The result demonstrated that the tumour 
area and fluorescence intensity value were directly correlated to each other. Therefore, the 
proliferation of cancer cells within the zebrafish can be represented by the tumour area. In the 
antiproliferation experiment, very low concentrations of ACA can significantly inhibit the 
proliferation of MCF7/LCC9-implanted zebrafish compared to the control.  
To conclude, this study suggested that ACA possessed antiproliferative effect in 
zebrafish xenograft model, which consistently correlated with the results from in vitro study 









MOLECULAR DOCKING SIMULATION 
 
6.1 Results: ACA’s affinity for protein targets 
This research was studied seven target molecules (HER2, AKT, ERK, ER, CDK6, uPA, 
and FGF2) to perform the docking simulation. Then ACA was determined the interaction 
energy and compared binding affinity to the standard ligands of a specific target. The studied 
targets were selected based on its molecular functions that crucially involved in signalling 
pathways of resistant-breast cancer cells. There were rationales for selecting these eight targets. 
Firstly, ACA was reported to be a potent NFκB inhibitor (156, 171). Secondly, ACA was 
reported that it could inhibit AKT and ERK in other cell lines (173, 188). These two molecules 
were reported to overexpress in resistant-breast cancer cells (67, 71, 72). Thirdly, according to 
the in vitro results from this research, it showed that ACA was able to downregulate AKT, 
ERK, NFκB mediated genes (uPA, FGF2), NCOA3, and HER2. Fourthly, oestrogen receptor 
and HER2 were selected because these two receptors were crucial for survival signallings for 
breast cancer (68, 69). Therefore, this study aimed to explore that ACA could bind to the 
upstream molecules of NFκB signalling (AKT and ERK), NFκB targeted genes (uPA, FGF2), 
oestrogen receptor, and HER2 (upstream molecule of MAPK/ERK1/2 pathway). Finally, 
CDK6 was selected as it was a critical molecule that required to work with cyclin D1, which 
was significant machinery for cell cycle in breast cancer cells (110-112). This research could 
not perform to all mediators due to the lack of standard molecules of a particular target to be 
compared with ACA. Thus, this study was selected these seven studied targets. 
 111 
The molecular docking results (Table 6.1.1) demonstrated that ACA has similar 
binding affinity for HER2, AKT, ERK, ER, CDK6, uPA, and FGF2 ranging from -21.61 to -
38.69 kcal/mol. However, among these seven different targets, the binding affinity of ACA 
toward uPA (-32.73 kcal/mol) and FGF2 (-21.61 kcal/mol) was in the range of their known 
inhibitors 4-IBTC (-37.43 kcal/mol) and Sm27 (-29.96 kcal/mol) respectively. Due to 
hydrophobic structure of ACA, van der Waals (green sphere) were the main interactions 
underlying protein-ligand complexation for both uPA and FGF2 proteins (Figure 6.1.1).  On 
the other hand, some electrostatic contributions (e.g., salt bridge, pi-sulfur, and pi-cation) were 
involved in the binding of 4-IBTC and Sm27 due to the polar moieties in their chemical 
structures. Notably, the key binding amino acid residues of ACA toward both uPA (Ser195, 
Ser214) and FGF2 (Lys119, Lys125, Lys129) as well as the hydrogen bond formation patterns 
(green dash) were relatively similar to those of the known inhibitors, implying that ACA could 
be an alternative potential inhibitor to uPA and FGF2. 
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HER2 Lapatinib -77.62 
1’-acetoxychavicol acetate -33.66 
AKT1 Ipatasertib -63.44 
1’-acetoxychavicol acetate -34.92 
ERK2 Sorafenib -53.92 




1’-acetoxychavicol acetate -35.68 
uPA 4-iodobenzo[b]thiophene-2-carboxamidine (4-IBTC) -37.43 
1’-acetoxychavicol acetate -32.73 
CDK6 Palbociclib -57.62 
1’-acetoxychavicol acetate -38.69 
FGF2 Sm27 -29.96 

















Figure 6.1.1. The 3D superimposed structures obtained from docking as well as the interaction 




The molecular docking results was performed by using CDOCKER interaction energy 
(kcal/mol) of seven studied protein-ligand complexes. Among seven substances, the 
CDOCKER interaction energy of ACA was close to the interaction energy of 4-IBTC (standard 
uPA ligand) and Sm27 (standard FGF2 ligand). CDOCKER interaction energy represented an 
inverse correlation with the binding affinity of protein-ligand complexes wherein, more 
negative energy value was more binding affinity (320). The lower the binding energy value 
means that the complex (ligand-protein interaction) is more stable. In addition, a negative value 
shows that the ligand bound spontaneously without consuming energy, as the negative Gibbs 
free energy (ΔG) is preferable for better binding affinity. This is because the change in ΔG of 
the system is negative when the system reaches an equilibrium state at constant pressure and 
temperature (320, 321). Also, the protein-ligand association extent is determined by the 
magnitude of the negative ΔG. Therefore, it can be considered that ΔG determines the stability 
of any given protein-ligand complex (322). The result supported that ACA showed preferable 
binding interaction to uPA and FGF2 than the other standard molecules. Albeit, the CDOCKER 
interaction energy of ACA was higher compared with the other five standard molecules; still, 
ACA could bind with lesser binding affinity to HER2, AKT1, ERK2, oestrogen receptor, and 
CDK6 compared to its known standard ligands. 
To conclude, the docking simulation study suggested that ACA could bind to the 
molecular targets involved in cancer proliferation, invasion, and angiogenesis, which bolstered 
the results of ACA effects on the in vitro anticancer activities. However, the binding affinity 
testing should be confirmed with more direct approaches such as direct biochemical methods 
(e.g. affinity chromatography) and quantitative proteomics (e.g. metabolic and chemical 
labelling). Also, some targets may not be appropriately used this docking simulation method 
because of the unavailability of published standard ligands to compare with the studied ligand. 
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CHAPTER 7 
GENERAL DISCUSSION AND CONCLUSION 
 
7.1 General discussion 
This study effectively isolated the pure ACA compound from the A. galangal; however, 
the structure of a pure ACA needed to be elucidated. Here in this study, ACA structure was 
elucidated using multidisciplinary spectroscopy. As of ACA was a known compound. 
Therefore, more sophisticated methods did not essential.  
This study demonstrated that ACA possesses cytotoxicity on both endocrine sensitive 
ER-positive MCF7 cell line and endocrine-resistant MCF7/LCC2 and MCF7/LCC9 cell lines 
without causing toxicity to normal fibroblast cell and the cytotoxic effect was more profound 
in the endocrine resistant cell lines. The mechanisms of ACA regarding its anticancer activities 
were through the suppression of HER2/MAPK/ERK1/2 and PI3K/AKT pathways. Upon 
repressed survival pathways, ACA can shift towards the apoptotic pathway through the 
upregulation of SAPK/JNK and cPARP and downregulation of the antiapoptotic proteins Mcl-
1 and Bcl-2. In addition, this study highlighted that ACA could downregulate NCOA3 protein. 
NCOA3 is the major coactivator of ER, which is an essential coactivator for ER signalling and 
functions in classical and nonclassical genomic pathways of ER. Consequently, ACA blocked 
the transcriptional activity of the ER-regulated genes. Apart from that, ACA, as a well-known 
NFκB inhibitor, can potentially crosstalk by blocking the transcription of NFκB-targeted genes 
via the inhibition of ERK1/2 and AKT phosphorylation wherein ERK1/2 and AKT activated 
NFκB activation. 
The antiproliferative effect of ACA was established in the endocrine-resistant engrafted 
zebrafish model. ACA effectively reduced tumour mass in ACA treated zebrafish/MCF7/LCC9 
without adverse effects to the zebrafish embryos. In addition, the acute toxicity experiment 
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reported as the LC50 of ACA at 24, 48, 72, and 96 hpf showed that ACA up to 20 µM does not 
significantly inhibit normal embryo stages development nor the normal formation of 
subintestinal vessels of the zebrafish. The result from in vivo antiproliferation of ACA in 
zebrafish model supported the result of antiproliferation of ACA in the in vitro study parts to 
demonstrate the function of ACA regarding inhibition of breast cancer cell proliferation.  
Furthermore, ACA repressed invasion in endocrine-resistant breast cancer cells by 
targeting the uPA system confirming via the pharmacological anti-invasion assay. VEGF and 
FGF2, a potent angiogenic factor, were also inhibited by ACA in both endocrine-sensitive and 
endocrine-resistant breast cancer cells.  Assuredly, the docking analysis results validated the 
inhibitory effects of ACA on FGF2 and uPA as its binding affinity was comparable to the 
standard ligands. The gene expression studies and docking experiments imply that ACA can 
have anti-angiogenic activity. However, more definities experiments are required to confirm 
this prediction. For example, in vitro anti-angiogenesis of ACA using endothelial cell 
proliferation assays, endothelial cell migration assays, and endothelial cell differentiation 
assays would be required. In vivo models could include, for example, zebrafish anti-
angiogenesis by visualising the developing vasculature, anti-angiogenesis in mice models (e.g. 
matrigel plug assay), and chick chorioallantoic membrane (CAM) assays. 
This in vitro study provided fundamental information of the anticancer activity of ACA 
in endocrine-resistant breast cancers that could be developed further for future development of 
ACA into clinical settings. It has also shown for the first time that ACA can inhibit NCOA3 
which is a well-established key protein in ER-positive hormonal-resistant breast cancer, both 
from in vitro studies and observations in cancer patients. Therefore, the bioactive ACA derived 
from the edible plant could be a promising compound to be used as adjuvant therapy or 
combination with tamoxifen for tamoxifen reversal sensitivity in breast cancer patients that 
develop resistance to tamoxifen, as well as other hormonal treatments. Also, this study showed 
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that ACA possessed activities on the HER2 receptor as well as its downstream survival 
molecules. Therefore, this novel knowledge can be developed further future studies of ACA on 
HER2-over-expressing breast cancer cells. The drug development process to develop any new 
chemical entities into the clinic, needs rigour, that includes defining the mechanism of action 
and direct target of the substance, pharmacokinetics, pharmacodynamics, adverse drug 
reactions, drug interactions (drug-drug, herb-drug, and food-drug interactions) as well as the 
dosage forms, stability and compatibility. In addition, ACA is a natural oily substance, and so 
could require additional processes such as drug delivery systems to improve the solubility and 
efficacy as well as reduce off-target toxicity of ACA. Hence, the difficulty of developing ACA 
as a novel chemotherapeutic agent would require the completion of many studies in order to 
be approved and established for clinical use. 
 
7.2 Limitation of this study 
In the in vitro studies of this thesis, the cytotoxic activity of ACA was studied in the 
endocrine-resistant MCF7/LCC2 and MCF7/LCC9 and the endocrine-sensitive MCF7 breast 
cancer cells. Tamoxifen was used as the appropriate positive control for MCF7cells (type), but 
it needed longer treatment time to show its cytostatic activity and there was no specific positive 
control for the endocrine-resistant cell lines. In addition, the in vitro studies were performed in 
two bases, which were Chulalongkorn University, Thailand and the University of Liverpool, 
UK. As the aims of the studies at Chulalongkorn University focused primarily in endocrine-
resistant cells, the experiments that needed to be performed in the University of Liverpool were 
involving the endocrine-sensitive MCF7 cells to be able to compare our ACA data on the 
endocrine resistance to endocrine sensitivity. Albeit, before starting the experiments, the 
comparison of the IC50 values of ACA on each cell line was required. We observed a small 
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variation in the IC50 of ACA in the cell lines which could possibly due to the different passage 
numbers of the cells within the two Universities and their freezing conditions. However, the 
effect of ACA on MCF7 cells in both bases did not show statistically different IC50 values. 
Hence, the MCF7 cell-based experiments were confidently performed (additional information 
can be found in Appendix B).  
This research succeeded in unpacking the effects of ACA on critical molecules involved 
in survival pathways of aggressive breast cancer cells. However, further investigation is 
required on identifying the specific mechanism of ACA’s action. The use of specific 
pharmacological inhibitor(s) or a combination of them targeting a particular pathway could 
possibly identify the dominant mechanism of ACA’s action. Additional studies to support the 
binding affinity evaluations are required as there are limitations in this docking simulation 
approach. In this study, ACA binding affinity to seven target proteins was compared with their 
standard ligands. However, this approach cannot evaluate all targets that may be involved in 
ACA’s action, such as the binding affinity of ACA on p65 subunit. The resistant MCF7/LCC9 
cell and ER-positive tamoxifen resistant cells have both been shown to overexpress the p65 
subunit of NF-kB, and hence it would have been informative to perform a binding affinity 
analysis of ACA on p65 subunit. However, this molecular docking simulation could not be 
performed on the p65 subunit as there is no standard ligand for p65 nuclear localisation 
inhibitors that have been identified. Consequently, this study could not compare the binding 
affinity between ACA and the standard ligand of p65 nuclear localisation inhibitors. In 
addition, other experiments, such as quantitative mass spectroscopy (direct biochemical 
methods) should be performed in order to demonstrate if ACA binds with p65 subunit, or other 
target proteins. As the methodology for the MCF7/LCC9 implanted zebrafish experiment was 
not published before and we had to set and evaluate all the appropriate conditions. It was not 
feasible to develop an additional MCF7/LCC2 implanted zebrafish. 
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7.3 Prospective study 
The analysis of ACA effects on a breast cancer gene expression panel should be 
performed in the future to compare the effect of ACA in the endocrine-sensitive and endocrine-
resistant breast cancer cells and identify differentially expressed genes for further analysis. In 
addition, in vitro studies on breast cancer cells with combinations of ACA and standard 
inhibitors (e.g. AKT inhibitor, ERK1/2 inhibitor, anti-HER2, and NFκB inhibitor) and analysis 
of targeted-gene and protein expressions (e.g. CCND1, C-myc, CXCR4, uPA, VEGF, FGF2) 
could provide a better insight into the mechanistic actions. ACA experiment on gene silencing 
(HER2, NCOA3) in breast cancer cells will support more evidence on validating the targets of 
ACA.  By silencing such genes in breast cancer cells, followed by analysing pERK1/2 and 
pAKT protein expressions will provide the information regarding the targets of ACA. Down-
regulating/silencing a gene is not the same as inhibiting a specific region and therefore, 
multiple methods are needed for confirming specific targets.  
Finally, the anti-invasion and anti-angiogenesis of ACA could be investigated in the 
future both in vitro models such as primary breast cancer cells and endothelial cells as well as 
in in vivo models such as zebrafish xenotransplantation and transgenic animals. 
 
7.4 Conclusion 
Taken together, our findings demonstrate the anti-cancer activity of the ACA through 
multiple pathways that directly influence the endocrine resistance of our tested cells, including 
concomitant pro-apoptotic signalling enhancement and inhibition of pro-survival molecules.  
Further investigation using specific inhibitors and/or gene silencing could provide a better 
















Figure 7.4.1. Proposed mechanism of ACA. The diagram shows the proposed mode of action 
of ACA which affects multiple molecules namely, HER2, PI3K/AKT, ERK1/2, and NCOA3. 
The effects lead to the downregulation of targeted molecules which involved in cell 
proliferation (CCND1, c-Myc), invasion (uPA, CXCR4), and angiogenesis (VEGF, FGF2). 





Appendix A /  Comparison of 1H NMR and mass spectra of ACA  
 
Figure A1. 1H NMR spectrum comparison of ACA. 1H NMR spectrum of ACA from Azuma 





Figure A2. Mass spectrum comparison of ACA. The mass spectrum of ACA from Lin et al (a) 




Mw of ACA  = 257.0786 – 22.9897 (mass of 
Na) 
  = 234.0889 
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Figure B1. The validation of IC50 in MCF7, MCF7/LCC2, and MCF7/LCC9 cell lines. This 
viability assay was performed in the University of Liverpool. IC50 values (µM) obtained by 
MTT assay after 48 hours of ACA treatment against MCF7, MCF7/LCC2, and MCF7/LCC9. 
Values showed as mean IC50 ± SEM, n = 3, *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, and ****p≤ 









































































Table B1. Comparison of IC50 values of ACA (48 h incubation) on 3 cell lines performed at 
Chulalongkorn University (CU) & University of Liverpool (UoL) 
Cell lines  IC50 (µM) - CU IC50 (µM) - UoL 
MCF7 11.78 µM ± 0.50 9.61 µM ± 1.09 
MCF7/LCC2 31.46 µM ± 1.00  25.80 µM ± 0.88* 
MCF7/LCC9 41.38 µM ± 1.80 34.58 µM ± 0.97* 
 




Appendix C /  Zebrafish husbandry 
Table C1. 60x Stock solution of E3 medium (323) 
Chemicals Amount (per litre) 
NaCl 17.53 g 
KCl 0.76 g 
CaCl2.2H2O 2.94 g 
MgSO4.7H2O  4.93 g 
 
Table C2. Concentration of 60x E3 medium stock solution (323) 
Chemicals Concentration 
NaCl 300 mM 
KCl  10.2 mM  
CaCl2 20 mM  
MgSO4 20 mM 
 
Preparation of 1x E3 medium (working solution) (323) 
Dilute 16.6 mL of 60x E3 medium with 933.4 mL of deionised water and adjust pH to 7.2-7.4 
and add 3 mL of 0.01% methylene Blue. After that adjust with deionised water to 1000 mL 





Figure C1. The husbandry of zebrafish and breeding station of zebrafish 
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Figure D1. Four atypical indicators of zebrafish embryos acute toxicity as followed OECD test 
guideline (TG 236) (324). (a) Coagulation of fertilised eggs, (b) Lack of detachment of the 





 Appendix E / Vessels formation and vessel staining of zebrafish 
 
 
Figure E1. Vascular network formation of zebrafish (325). Palatocerebral artery; PLA, 
communicating vessel; CMV, nasal ciliary artery; NCA, segmental arteries; aISV, subintestinal 










Figure E2. Alkaline phosphatase stained-zebrafish and alkaline phosphatase staining reaction 







Figure E3. Validation of incubation time for alkaline phosphatase staining in zebrafish at 72 
hpf and 90 hpf 
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Appendix F / Conference Presentations 
1) Revision process of Planta Medica journal 
“1’ Acetoxychavicol acetate from Alpinia galanga represses Proliferation, Invasion, and 
induces Apoptosis via HER-2 signalling in Endocrine-Resistant Breast Cancer cells” 
 
2) 2019 NCRI Cancer Conference (3-5 November 2019), Scottish Event Campus, 
Glasglow, UK 
Poster and silent theater presentations: “Antiproliferation and anti-invasion of 1’-
Acetoxychavicol acetate on hormonal-resistant breast cancer cells”. Nalinee Pradubyat, 
Athina Giannoudis, Carlo Palmieri, Wannarasmi Ketchart 
 
3) North West Cancer Research Centre (Friday 26th April 2019) - the University of 
Liverpool Annual Scientific Symposium 2020, Victoria Gallery & Museum, University of 
Liverpool, UK.  
Poster presentation: “1’-acetoxychavicol acetate represses proliferation and invasion and 
induces apoptosis of endocrine-resistant breast cancer cells” Nalinee Pradubyat, Athina 
Giannoudis, Panupong Mahalapbutr, Chalermchai Mitrpant, Taha Elmitwali, Carlo Palmieri, 
Wannarasmi Ketchart 
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